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ABSTRACT 
Each year, over 50 million Americans suffer from persistent pain, including debilitating 
headaches, joint pain, and severe back pain. Although morphine is amongst the most effective 
analgesics available for the management of severe pain, prolonged morphine treatment results in 
decreased analgesic efficacy (i.e., tolerance). Despite significant headway in the field, the 
mechanisms underlying the development of morphine tolerance are not well understood. The 
midbrain ventrolateral periaqueductal gray (vlPAG) is a primary neural substrate for the 
analgesic effects of morphine, as well as for the development of morphine tolerance. A growing 
body of literature indicates that activated glia (i.e., microglia and astrocytes) facilitate pain 
transmission and oppose morphine analgesia, making these cells important potential targets in 
the treatment of chronic pain. Morphine affects glia by binding to the innate immune receptor 
toll-like receptor 4 (TLR4), leading to the release of proinflammatory cytokines and opposition 
of morphine analgesia. Despite the established role of the vlPAG as an integral locus for the 
development of morphine tolerance, to date, no studies have examined the role of glia activation 
within this region. Additionally, the role of TLR4 in the development of tolerance has not been 
elucidated. This dissertation seeks to address the lack of knowledge regarding the role of vlPAG 
glia and TLR4 in the development of morphine tolerance by (1) Characterizing the effects of 
chronic morphine and peripheral inflammatory pain on vlPAG glial cell activity; (2) 
Investigating the role of glia activation within the vlPAG in the development of morphine 
tolerance; (3) Characterizing the role of the glial receptor TLR4 within the vlPAG in the 
development of morphine tolerance; and (4) Characterizing the glia to neuron signaling 
mechanisms involved in the development of morphine tolerance. These experiments, together, 
provide novel information about the mechanism by which central nervous system glia regulate 
morphine tolerance, and identify a potential therapeutic target for the enhancement of analgesic 
efficacy in the clinical treatment of chronic pain. 
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CHAPTER 1: Introduction 
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Opioids and the Management of Pain 
The perception of pain is an important evolutionary phenomenon that allows escape from 
danger, avoidance of harmful stimuli, and attention to tissue damage. However, chronic pain 
perception in the absence of an ongoing injury, or during treatment of an illness, is aversive 
without purpose and detrimental to quality of life. Chronic pain, defined as pain lasting more 
than three months, impacts approximately 55% of the population over the age of 20, and includes 
debilitating headaches, joint pain, severe back pain, and cancer-related pain1,2. Despite their 
discovery thousands of years ago, opiates remain the most common and effective option for pain 
management3. Indeed, over 90% of chronic pain sufferers receive some form of opiate therapy 4, 
with morphine being amongst the most commonly prescribed drugs.  
In addition to modulating pain, opiates have widespread central and peripheral effects, 
many of which interfere with the beneficial aspects of opiates5. Indeed, the negative side effects 
associated with opiate consumption, including respiratory depression, gastrointestinal immotility, 
and addiction, render these drugs unsatisfactory for long-term pain management1,6.  Although a 
multitude of opioids (man-made drugs sharing similar structures with the plant-derived opium6) 
were synthesized in hopes of harnessing the natural analgesic potency of opiates while 
minimizing the negative side effects, few are as potent as morphine, and the pinnacle, analgesia 
without the side-effect profile, has not been realized5.   
The average duration of opioid consumption for chronic pain management is 105 days7. 
Prolonged morphine treatment reduces analgesic efficacy (i.e., tolerance), thereby requiring 
steadily larger doses of opiates for the maintenance of analgesia3. Dose escalation increases the 
risk of developing negative side effects, including anti-analgesia, addiction, withdrawal, and 
respiratory depression4, and is not always sufficient to overcome tolerance and reinstate 
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analgesic efficacy3. Indeed, opioid tolerance is a significant impediment for sufficient pain relief 
in approximately 60% of patients8. Remarkably, the mechanisms underlying the development of 
morphine tolerance are unknown.  
 
Opioid Action in the CNS: The PAG & the Descending Analgesic Pathway 
The midbrain periaqueductal gray (PAG) and its descending projections to the rostral 
ventromedial medulla (RVM) and spinal cord comprise a critical neural circuit for both 
endogenous and exogenous opioid-mediated analgesia9-13. The PAG was first identified as an 
essential neural substrate for pain modulation in the 1960s, when it was demonstrated that 
electrical stimulation of the rat PAG produces analgesia so profound as to allow for invasive 
abdominal surgery to be performed in the absence of anesthesia14,15. In humans, electrical 
stimulation of the PAG is still used today for the management of intractable pain16-18. PAG 
stimulation produced analgesia is attenuated by intra-PAG injection of the mu opioid receptor 
(MOR) antagonist naloxone,19 suggesting an opioid-dependent mechanism.  
The PAG contains a high density of MOR containing neurons,20-22 and microinjection of 
opiate antagonists into the PAG significantly attenuates the analgesic effects of systemic 
morphine23-25. Similarly, site-specific lesions of PAG MOR-containing neurons (using the 
cytotoxin saporin (aka ribosome inactivating protein; RIP) conjugated to the MOR ligand 
Dermorphin) significantly reduce the antinociceptive effects of systemic morphine suggesting 
that PAG MOR is critical for morphine action26. The density of MOR immunoreactivity within 
the vlPAG is positively correlated with the degree of analgesia produced by morphine, such that 
male rats with normal levels of MOR immunoreactivity in the vlPAG have significantly lower 
ED50 values (4.07 mg/kg) compared with animals in which MOR levels were reduced 2-fold 
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(12.55 mg/kg).  Indeed, in animals with low PAG MOR, systemic administration of 10 mg/kg of 
morphine results in only a 20% maximum possible analgesic effect in comparison to 100% in 
animals with a complete complement of MOR. Together, these data indicate that the PAG is an 
essential site for opioid-mediated analgesia.  
Morphine and other opioids bind to neuronal MOR6 , a prototypical G-protein coupled 
receptor (GPCR), and are generally thought to elicit analgesia by hyperpolarizing GABAergic 
neurons (‘GABA disinhibition hypothesis’)9,11,27-33. Indeed, it is the release from tonic 
GABAergic inhibition that allows morphine to inhibit pain.  In vitro, MOR binding on PAG 
neurons inhibits mIPSP frequency and decreases the probability of presynaptic GABA 
release31,34. In vivo, injection of GABA antagonists into the PAG partially mimics the effects of 
morphine35. Physiologically, morphine binding to vlPAG MOR hyperpolarizes GABAergic 
interneurons34,36, thereby releasing vlPAG-RVM projection neurons from local tonic inhibition36. 
Removal of this tonic inhibition results in the net excitation of RVM neurons, which then signal 
to the spinal cord to inhibit nociceptive dorsal horn neurons and produce antinociception37-39 
(Figure 1.1). Indeed, lesions of the RVM and spinal dorsal horn abolish PAG stimulation-
produced antinociception, indicating that the PAG-RVM-spinal cord circuit is necessary for both 
exogenous and endogenous pain modulation40,41. 
Neuronal Mechanisms of Opioid Tolerance 
In addition to being a critical locus for both endogenous and exogenous pain modulation, 
the vlPAG is also necessary and sufficient for the development of morphine tolerance24,42-51. 
Chronic vlPAG opioid administration results in the rapid development of behaviorally and 
physiologically defined opioid tolerance. In addition, repeated intra-vlPAG microinjections of 
morphine49 or the potent MOR agonists fentanyl43 or DAMGO47,49 result in tolerance to 
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systemically administered morphine. Further, chronic administration of morphine into the 
ventrolateral, but not lateral or dorsal, PAG induces morphine tolerance51; this effect remains 
when the downstream target (RVM) is inhibited with the GABA agonist muscimol. Interestingly, 
these behavioral and electrophysiological changes underlying tolerance are prevented by intra-
vlPAG injections of the opioid receptor antagonist naltrexone24, indicating that the vlPAG is 
sufficient for the development of morphine tolerance24.  
While the mechanisms by which morphine tolerance develops are not entirely 
understood, many current hypotheses include a role for increased glutamatergic and/or decreased 
GABAergic signaling31 that ultimately oppose the hyperpolarizing effects of morphine. 
Cerebrospinal fluid (CSF) from morphine-tolerant humans contains significantly higher levels of 
both glutamate and aspartate52, and morphine challenge increases glutamate in the CSF of 
morphine tolerant rats53. Increased expression of AMPA and NMDA receptor subunits54 and 
increased NMDA receptor binding55 in the rat spinal cord has been shown to accompany 
tolerance development. Along these same lines, blockade of spinal cord glutamatergic signaling 
by intrathecal administration of NMDA56-61 and AMPA62,63 receptor antagonists attenuates 
morphine tolerance. Together, these data indicate that, at least at the level of the spinal cord, 
opioid tolerance is accompanied by an increase in the excitatory neuroenvironment that is 
mediated by changes in glutamatergic signaling.  
Studies examining the cellular responses of PAG neurons indicate that morphine 
tolerance, induced by repeated systemic or intra-vlPAG morphine, decreases the ability of 
opioids to initiate signaling through the PAG-RVM descending analgesic circuit44,45. Repeated 
pharmacological activation of the PAG-RVM circuit via direct microinjection of the excitatory 
amino acid agonist kainate or the GABAergic antagonist bicuculine is not sufficient to induce 
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tolerance, indicating that tolerance requires opiate activation of MOR-expressing GABAergic 
neurons that synapse onto PAG-RVM output neurons48. Indeed, Morgan and colleagues recently 
demonstrated that chronic vlPAG microinjections of morphine results in tolerance that is 
dependent on alterations in pre- and post-synaptic GABA release42. Chronic systemic morphine 
results in tolerance as evidenced by a decreased ability of MOR agonists to inhibit Ca2+ and 
activate K+ channels in dissociated neuronal cultures from the PAG or PAG slices64. While 
NMDA receptor signaling is not important for PAG-mediated opioid tolerance65,66, data from the 
PAG supports a role for increased neuroexcitability in tolerance development. For example, 
intra-PAG microinjections of the cholecystokinin (CCK) antagonist proglumide prevent and 
even reverse tolerance to repeated PAG microinjections of morphine67. CCK excites neurons by 
opening depolarizing currents and inhibiting K+ conductance68-70, thereby directly opposing the 
mechanisms by which morphine hyperpolarizes neurons. Together, these data suggest that 
increased neuroexcitability at the level of the PAG significantly contributes to opioid analgesic 
tolerance by decreasing the ability of opioids to hyperpolarize neurons.  
 
Glial Mechanisms of Opioid Tolerance 
Since the 1990’s basic research has shifted focus from exclusive investigation of neuronal 
mechanisms underlying opiate analgesia and tolerance to investigation of both neuronal and 
central nervous system (CNS) glial involvement. It is now well established that chronic 
morphine induces a robust neuroinflammatory response in the CNS that enhances neuronal 
excitability and contributes to tolerance71-87. While the importance of the vlPAG in tolerance 
development is well established, the investigation of glial involvement in opiate signaling has 
been limited to spinal and medullary loci81,85,88-90.  
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Several lines of evidence implicate opioids as activators of CNS astrocytes and 
microglia85. In the spinal cord, morphine increases protein levels of the microglia and astrocyte 
activity markers OX-42 and glial fibrillary acidic protein (GFAP), respectively,71,72,91 and 
induces release of glially derived proinflammatory cytokines73,74,81,84,86,87,90. Proinflammatory 
cytokines have been shown to decrease GABA receptor expression, increase the number and the 
conductance of AMPA and NMDA receptors, decrease glutamate transporter proteins, and 
decrease outward potassium currents85, resulting in an overall increase in neuroexcitability. 
Functionally, administration of the glial metabolic inhibitors propentofylline, fluorocitrate, and 
minocycline reduce spinal OX-42, GFAP, and cytokines, and attenuate morphine 
tolerance72,76,87,91-97.  Importantly, glial release of cytokines increases exponentially with repeated 
morphine administration,84 making these excitatory substances key players in the development of 
morphine tolerance. 
Both morphine tolerance and opioid-induced sensitivity to pain (hyperalgesia) following 
repeated exposure to morphine is still observed in neuronal opioid receptor (µ, δ, and κ) knock 
out mice98, suggesting that the anti-analgesic effects of morphine are not mediated by traditional 
opioid receptor signaling. Recent in vivo and in vitro data confirm this, and demonstrate that the 
proinflammatory effects of morphine are mediated through the innate immune receptor Toll-like 
receptor 4 (TLR4)81. TLR4 is found on microglia, and to a lesser degree, astrocytes99,100. 
Opioids, including morphine, bind to the glycoprotein myeloid differentiation factor-2 (MD-2) 
on TLR478,79, and initiate an inflammatory response through nuclear factor kappa B (NF-κB) 
activation and p38 mitogen activated protein kinase (MAPK) phosphorylation81. Activation of 
the NFκB pathway results in the robust release of proinflammatory cytokines including tumor 
necrosis factor alpha, (TNF), Interleukin 1 beta (IL-1β), and Interleukin 6 (IL-6)78,79,81.  Spinal 
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TLR4 activity opposes the acute effects of morphine, including antinociception, and contributes 
to opioid-induced hyperalgesia78,79. While the brain loci through which TLR4 mediates morphine 
tolerance have not been investigated, systemic TLR4 antagonists prevent tolerance to systemic 
morphine78. 
A nearly ubiquitous characteristic of opioid-induced neuroinflammation is TNF 
production, likely mediated via TLR4. Chronic systemic101 or intrathecal morphine 
administration increases TNF mRNA84,86,102,103 and protein53,86,101,102,104,105 in the rodent spinal 
cord, and TNF levels increase with the chronicity of morphine treatment84. Inhibition of spinal 
TNF signaling decreases morphine-induced release of proinflammatory cytokines (e.g., TNF, IL-
1β, and IL-6) and activation of p38 MAPK54,102,106, indicating that TNF induces a positive 
feedback loop of neuroinflammation that contributes to decreased morphine efficacy. 
Functionally, immunomodulatory drugs that attenuate, abolish, or even reverse morphine 
tolerance (e.g., ibudilast (AV411)97,107, minocycline76,91,96,97,108, fluorocitrate72,82, 
propentofylline82,87,93,94,109) decrease the expression of TNF. However, these immunomodulatory 
drugs have widespread and non-specific effects, altering expression levels of several cytokines 
implicated in opioid tolerance, including IL-1β86,101,110 and IL-686,87,101. While these data indicate 
that spinal TNF plays a significant role in morphine-induced inflammation and the development 
of morphine tolerance72-74,76,84-87,93,111,112, remarkably, very few studies have directly tested the 
role of TNF in isolation54,102,106.  
 
Dissertation Aims 
Despite the established role of the vlPAG as an integral CNS locus for morphine action, 
including analgesia and tolerance, studies investigating the modulatory role of glia and cytokine 
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release have been limited to medullary and spinal loci. The role of PAG TLR4 in the 
development of tolerance has not been elucidated. This dissertation addressed the dearth of 
knowledge regarding the role of vlPAG glia and TLR4 in the development of morphine tolerance 
by (1) characterizing vlPAG glial cell activity in tolerant and non-tolerant male rats in the 
absence and presence of a persistent pain state using behavioral, immunohistochemical, and 
western blot analyses; (2) investigating the necessity of vlPAG astrocytes and microglia in the 
development of morphine tolerance using behavioral analysis coupled with site-specific 
pharmacological injections of glial metabolic inhibitors; (3) investigating the necessity and 
sufficiency of vlPAG TLR4 in the development of morphine tolerance using behavioral analysis 
coupled with site specific injections of TLR4 agonists and antagonists; and (4) investigating the 
necessity of vlPAG TNF in the development of morphine tolerance using behavioral analysis 
coupled with lenti-viral or pharmacological administration of an anti-TNF biologic. In these final 
studies, expression levels of TNF, IL-1β, IL-6, IL-10, and TLR4 were quantified in the vlPAG 
using quantitative RT-PCR while in situ hybridization was used to quantify mRNA levels of the 
glutamate transporters GLT-1, GLAST, and EAAC1. Together, these experiments provide novel 
information about the mechanisms by which central nervous system glia modulate morphine 
action and the development of tolerance, and will identify potential therapeutic targets for the 
enhancement of analgesic efficacy in the clinical treatment of chronic pain (Figure 1.2). 
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Chapter 1 Figures 
 
Figure 1.1 A schematic of the descending inhibitory pathway for pain modulation. 
Adapted from Guo et al. 2006113. Primary afferents relay information regarding noxious stimuli 
through the dorsal root ganglia (DRG) to terminate within the dorsal horn (DH) of the spinal 
cord. This noxious input is subject to tonic descending inhibition via projections from the 
midbrain periaqueductal gray (PAG) to the brainstem rostral ventromedial medulla (RVM) and 
the spinal cord DH.  
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Figure 1.2 A schematic diagram illustrating core hypotheses to be tested. 
We hypothesize that chronic morphine binds to glial TLR4 to induce the release of soluble TNF. 
Soluble TNF increases the neuronal excitability of PAG neurons by increasing glutamatergic 
signaling, thereby decreasing morphine’s ability to hyperpolarize GABAergic interneurons. 
GABAergic signaling tonically inhibits PAG-RVM projection neurons, thereby preventing 
signaling through the descending analgesic circuit. 
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 Abstract 
Morphine is among the most prevalent analgesics prescribed for chronic pain. However, 
prolonged morphine treatment results in the development of analgesic tolerance. An abundance 
of evidence has accumulated indicating that CNS glial cell activity facilitates pain transmission 
and opposes morphine analgesia. While the midbrain ventrolateral periaqueductal gray (vlPAG) 
is an important neural substrate mediating pain modulation and the development of morphine 
tolerance, no studies have directly assessed the role of PAG-glia.  Here we test the hypothesis 
that morphine-induced increases in vlPAG glial cell activity contribute to the development of 
morphine tolerance. As morphine is primarily consumed for the alleviation of severe pain, the 
influence of persistent inflammatory pain was also assessed. Administration of morphine, in the 
absence of persistent inflammatory pain, resulted in the rapid development of morphine tolerance 
and was accompanied by a significant increase in vlPAG glial activation.  In contrast, persistent 
inflammatory hyperalgesia, induced by intraplantar administration of Complete Freund’s 
Adjuvant (CFA), significantly attenuated the development of morphine tolerance. No significant 
differences were noted in vlPAG glial cell activation for CFA-treated animals versus controls. 
These results indicate that vlPAG glia are modulated by a persistent pain state, and implicate 
vlPAG glial cells as possible regulators of morphine tolerance. The development of morphine 
tolerance represents a significant impediment to its use in the management of chronic pain. We 
report that morphine tolerance is accompanied by increased glial cell activation within the 
vlPAG, and that the presence of a persistent pain state prevented vlPAG glial activation and 
attenuated morphine tolerance. 
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Introduction 
Chronic pain, defined as pain lasting more than 3-6 months, will affect more than one in 
three Americans at some point in their life1,2. Although morphine is one of the most commonly 
prescribed analgesics4, secondary side effects (e.g., tolerance) limit its efficacy for long-term 
chronic pain treatment45,114-116. In the absence of pain, morphine tolerance, defined as the 
requirement for steadily larger doses of opioids to achieve the same analgesic effect, develops 
quite rapidly45,117,118. In contrast, clinical studies have consistently reported that the latency to 
develop morphine tolerance is increased in chronic pain sufferers, although dose escalation is 
eventually required for the maintenance of analgesic efficacy3. Dose escalation leads to increased 
risk of developing additional negative side effects, including anti-analgesia, addiction, 
withdrawal, and respiratory depression4, and is not always sufficient to overcome tolerance and 
reinstate analgesic efficacy3. As over 90% of chronic pain sufferers are treated with opioids4, 
including morphine, elucidation of the mechanisms by which morphine tolerance develops 
warrants investigation. 
The midbrain ventrolateral periaqueductal gray (vlPAG) and its descending projections to 
the rostral ventromedial medulla (RVM) and spinal cord, comprises an important neural circuit 
for both endogenous and exogenous opioid-mediated analgesia9-13. In rats, chronic subcutaneous 
injections of morphine result in tolerance to subsequent doses of morphine, an effect that is 
eliminated by intra-vlPAG injections of the opioid receptor antagonist naltrexone24. In addition, 
chronic intra-vlPAG injections of morphine induce tolerance, and this effect remains when the 
RVM, the primary downstream target of the PAG, is inhibited with the GABA agonist 
muscimol24.  
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An abundance of evidence has accumulated indicating that systemic morphine 
administration activates glial cells, including microglia and astrocytes51,72,85,86,91,92,119. Song and 
Zhou (2001) reported that chronic morphine administration results in the activation of astrocytes 
within the cingulate cortex, hippocampus and spinal cord, and that blockade of glial activation 
within the spinal cord attenuates the development of morphine tolerance. Since then, a myriad of 
studies have been published implicating glia activation in the development of morphine 
tolerance85,88 and pain facilitation93,120,121.  While it is clear that the activation of microglia and 
astrocytes contribute to the development of morphine tolerance, no studies have examined the 
role of activated glia within the PAG, a primary site of morphine action. Similarly, the influence 
of a persistent inflammatory pain state on PAG glial cell activation has not been assessed. The 
present study tested the hypothesis that morphine-induced increases in vlPAG glial cell activity 
contribute to the development of morphine tolerance, and that persistent inflammatory pain alters 
this activation, resulting in the attenuation of morphine tolerance.  
Materials and Methods 
Subjects 
Weight-matched (250-350g) male Sprague Dawley rats (Charles River, Wilmington, 
MA) were pair-housed on a 12:12 hour light: dark cycle. Access to food and water was available 
ad libitum throughout the experiments except during behavioral testing. All studies were 
approved by the Institutional Animal Care and Use Committee (IACUC) at Georgia State 
University, and performed in strict compliance with Ethical Issues of the International 
Association for the Study of Pain (IASP) and National Institute of Health (NIH). All efforts were 
made to reduce the number of animals used in these experiments and to minimize any possible 
suffering by the animal. 
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Persistent Inflammatory Hyperalgesia 
In a subset of animals, persistent inflammatory hyperalgesia was induced by injection of 
complete Freund’s adjuvant (CFA; Mycobacterium tuberculosis; Sigma; 200 µl), suspended in 
an oil/saline (1:1) emulsion, into the plantar surface of the right hindpaw as previously 
described45,122,123. As intraplantar saline administration results in a short-term inflammatory 
response, control animals were restrained in a similar manner but did not receive an intraplantar 
injection. 
Experiment 1: Influence of Persistent Inflammatory Pain on Morphine Tolerance 
Twenty-four hours following intraplantar CFA injection or handling, animals were 
administered morphine (5 mg/kg, sc; NIDA) or saline (1 ml/kg, sc) once a day for three 
consecutive days (CFA+Morphine; CFA+Saline; Handled+Morphine; Handled+Saline). The 5 
mg/kg dose was chosen based on our previous studies demonstrating this to be the 50% effective 
dose (ED50) for systemic morphine in male rats122,124,125. Baseline nociceptive thresholds were 
measured before morphine or saline injections, and 15 minutes following the first and last 
injection (Injection 1 and Injection 3, respectively). Tolerance was assessed on Day 5 (Day 1 
being CFA administration), by injecting cumulative doses of morphine every 20 min, resulting in 
doses of 3.2, 5.6, 8.0, 10.0 and 18.0 mg/kg as previously described45.  Nociception was assessed 
using the paw thermal stimulator126 15 min after each injection122.  Briefly, for this test, the rat is 
placed in a clear Plexiglas box resting on an elevated glass plate maintained at 30oC. A radiant 
beam of light is positioned under the hindpaw and the time for the rat to remove the paw from 
the thermal stimulus is electronically recorded as the paw withdrawal latency (PWL). The 
intensity of the beam was set to produce basal withdrawal rates of 7-9 seconds.  A maximal PWL 
of 20.48 seconds was used to prevent excess tissue damage due to repeated application of the 
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noxious thermal stimulus. Animals were acclimated to the testing apparatus (30 minutes a day 
for 3 consecutive days) at the start of the experiment. All behavioral testing took place between 
12:00pm and 5:00pm (lights on at 7:00am). All testing was conducted blind with respect to 
group assignment (i.e., morphine or saline treatment). 
Behavioral data analysis and presentation 
Behavioral data are expressed in raw seconds. Paw withdrawal latency data were 
analyzed using repeated measures ANOVA for significant main effect of pain (CFA or handled) 
and treatment (morphine or saline) across dose. Pre-planned t-tests were used to determine 
specific group and dose differences when a significant main effect was observed. All values are 
reported as Mean + S.E.M.; p< 0.05 was considered statistically significant.  
Experiment 2: Anatomical Assessment of Morphine Tolerance 
Twenty-four hours following intraplantar CFA or handling, animals were administered 
morphine (5 mg/kg; sc) or saline (1 ml/kg; sc) once a day for three consecutive days as described 
above (CFA+Morphine, CFA+Saline, Handled+Morphine, Handled+Saline). One hour 
following the last injection of morphine or saline, animals were given a lethal dose of Nembutal 
(160 mg/kg; i.p.) and transcardially perfused with 250 ml of 0.9% sodium chloride containing 
2% sodium nitrite as a vasodilator to remove blood from the brain. Immediately following blood 
removal, 300 ml of 4% paraformaldehyde in 0.1M phosphate buffer containing 2.5% acrolein 
(Polysciences Inc.; Warrington, PA) was perfused through the brain as a fixative. A final rinse 
with 250 ml of sodium chloride/sodium nitrite solution was perfused through the brain to remove 
any residual acrolein. Brains were removed and placed in a 30% sucrose solution and stored at 
4°C until sectioning. To examine the acute effects of morphine on vlPAG glia activation, a 
separate group of animals received one sc injection of morphine (or saline) and were sacrificed 1 
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or 24 hours later. A separate group of animals (CFA+Morphine, CFA+Saline, 
Handled+Morphine, Handled+Saline) were decapitated immediately following treatment for 
western blot analysis. Brains were removed, flash frozen in 2-methyl-butane on dry ice, and 
stored at -80°C. 
Immunohistochemistry 
Hallmarks of glial cell activity include increased cytokine release that correlates with 
increased expression of the protein markers glial fibrillary acidic protein (GFAP; astrocytes), and 
CD-11b (OX-42; microglia)86. Further, increased glial cell activity is evidenced by a profound 
shift in morphology that can be easily visualized using immunohistochemistry for GFAP and 
OX-42127. Perfused brains were sectioned into 25µm coronal sections with a Leica 2000R 
freezing microtome and stored free-floating in cryoprotectant-antifreeze solution128 at -20°C. A 
1:6 series through the rostrocaudal axis of each brain was processed for GFAP and OX-42 
immunoreactivity using standard immunohistochemical techniques129. Briefly, sections were 
rinsed extensively in potassium phosphate-buffered saline (KPBS) immediately followed by a 
20-minute incubation in 1% sodium borohydride. The tissue was then incubated in primary 
antibody solution (rabbit anti-GFAP 1:5,000 or rabbit anti-OX42 1:1000; Abcam) in KPBS 
containing 1.0% Triton-X for one hour at room temperature followed by 48 hours at 4°C. After 
rinsing with KPBS, the tissue was incubated for one hour in secondary antibody (biotinylated 
IgG goat anti-rabbit 1:600), rinsed with KPBS, and then incubated for one hour in an avidin-
biotin peroxidase complex (1:10; ABC Elite Kit, Vector Labs). After rinsing in KPBS and 
sodium acetate (0.175 M; pH 6.5), GFAP or OX-42 immunoreactivity was visualized as a black 
reaction product using nickel sulfate intensified 3,3’-diaminobenzidine (DAB) solution (2 
mg/10ml) containing 0.08% hydrogen peroxide in sodium acetate buffer. After 15 minutes, 
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tissue was rinsed in sodium acetate buffer followed by KPBS. In a subset of sections, GFAP 
(Rabbit anti-GFAP 1:3,000; Abcam) or OX-42 (Mouse anti-CD11b 1:3000; Serotec) was 
visualized using a fluorescent secondary antibody (goat anti-rabbit Dylight488 1:50 for GFAP 
and rabbit anti-mouse Cy3 1:50 for CD11b; Jackson Immunoresearch Laboratories).  Following 
secondary incubation, sections were rinsed in KPBS. DAB and fluorescent sections were 
mounted out of KPBS onto gelatin-subbed slides, air-dried and dehydrated in a series of graded 
alcohols. Tissue-mounted slides were then cleared in Xylenes and glass cover-slipped using 
Permount for DAB reactions or Krystalon for fluorescence.  
Western blotting 
Flash frozen brains were sectioned at 300mm on a cryostat (Leica, Buffalo Grove, IL) 
and mounted onto slides. One-millimeter bilateral micropunches were taken from 6 levels for the 
vlPAG (Bregma -8.52, -8.28, -7.92, -7.68, -7.20, and -6.96)130 and 6 levels of the superior 
colliculus (Bregma -7.68, -7.20, -6.96, -6.60, -6.24, and -5.80)130, and homogenized in a 10mM 
HEPES buffer (pH 7.2). Equal amounts of protein (2mg) along with a standard marker (Bio-Rad, 
Hercules, CA) were run at 100V for 2 hours through 10% Tris-HCl polyacrylamide gels (Bio-
Rad, Hercules, CA), and electro-transferred at 4°C on ice at 250mA for 2 hours onto PVDF 
membranes (0.2mm pore size; Bio-Rad, Hercules, CA). Membranes were blocked with 5% milk 
in TBS-Tween 20 (1%) at 4°C overnight, and probed with rabbit anti-GFAP primary antibody 
(1:300,000; Abcam) in 2% milk/TBS-Tween 20 (1%) for 3 hours at room temperature followed 
by a 30 minute incubation in HRP-conjugated goat anti-rabbit secondary (1:5000; Abcam) in 2% 
milk/TBS-Tween 20 (1%). Rabbit anti-b-actin primary (1:10,000; Novus Biologicals) was 
included as a control for protein loading. Membranes were stripped and reprobed with mouse 
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anti-rat CD11b (OX-42, 1:700; Serotec) followed by HRP-conjugated goat anti-mouse (OX-42; 
1:5000; Abcam) and HRP-conjugated goat anti-rabbit (b-actin; 1:5000; Abcam) secondaries.    
Anatomical data analysis and presentation 
Levels of GFAP and OX-42 immunoreactivity in the vlPAG were compared across 
treatment groups using semi-quantitative densitometry as previously described45,131. To 
determine if the observed changes in glia activation were limited to the vlPAG, sections through 
the superior colliculus (SC), a region containing a high density of m opioid receptors (MOR) but 
not implicated in opioid modulation of pain, were also analyzed. 12-bit grayscale images that 
included the region of interest (ROI) were captured using a QImaging Retiga EXi CCD camera 
(Surrey, BC, Canada) and iVision Image analysis software (Biovision Technologies, Exton, PA). 
Grayscale values for each image were inverted so that higher values were representative of 
increased staining levels. Images of three slices through each ROI for each animal were analyzed 
and data sampled unilaterally. Data sampling occurred by using the drawing tools in iVision to 
outline the ROI and using the “measure” function to determine an average grayscale pixel value 
for the outlined area. ROI measures were corrected for nonspecific binding by subtraction of 
background measure taken from gray matter adjacent to the ROI.  Data were analyzed across 3 
representative levels through the rostral-caudal axis of the vlPAG (Bregma -7.08, -7.68, and -
8.30)130 and superior colliculus (Bregma -7.68, -6.24, and -5.80) 130 as previously described45. 
Densitometry values are presented as the mean + S.E.M. density of immunoreactivity. Data were 
analyzed using an ANOVA to determine significant main effects of treatment (morphine, saline) 
and pain (CFA, handled). Fisher’s post hoc tests were used to determine specific group 
differences when a significant main effect was observed; p < 0.05 was considered statistically 
significant. For Western blots, band intensities for tissue from the vlPAG and superior colliculus 
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were visualized at 55kD (GFAP) and 160kD (CD11b), and quantified using ImageJ (NIH, USA) 
analysis software, as a relative intensity of GFAP or CD11b band divided by the intensity of the 
b-actin band. Data are expressed as the mean ratio + S.E.M of protein of interest/b-actin. Data 
were analyzed for significant main effects of treatment (morphine, saline) and pain (CFA, 
handled) using an ANOVA, and Fisher’s HSD was used for post-hoc analysis; p < 0.05 was 
considered statistically significant. 
Results 
Experiment 1: Persistent Peripheral Inflammation Attenuated Morphine Tolerance  
To assess the initial analgesic potency of morphine, and the degree and time course for 
development of morphine tolerance, paw withdrawal latencies (PWL) were determined for both 
the injured (ipsilateral; right) and uninjured (contralateral; left) hindpaws at baseline, and after 
Day 1 and Day 3 of morphine or saline. Contralateral (uninjured) PWL did not differ between 
CFA+Saline and Handled+Saline groups at any time point (Figure 2.1A). By contrast, 
intraplantar CFA significantly decreased ipsilateral PWL 24, 48, and 96 hours post injection as 
compared with handled controls (CFA+Saline versus Handled+Saline; Figure 2.1B) indicating 
the development of persistent hyperalgesia. Administration of morphine on Day 1 and 3 
significantly increased both contralateral and ipsilateral PWLs as compared with saline controls 
(Figure 2.1A and B, respectively). For the contralateral paw, administration of morphine (Day 1) 
produced comparable levels of analgesia in the CFA+Morphine and Handled+Morphine groups 
(Figure 2.1A). However, the degree of analgesia produced by morphine on Day 3 was 
significantly attenuated in the Handled+Morphine vs. the CFA+Morphine animals, suggesting 
the development of morphine tolerance (Figure 2.1A). In the ipsilateral hindpaw, administration 
of morphine on Day 1 produced anti-hyperalgesia in CFA treated animals as indicated by a 
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return to normal baseline PWL (CFA+Morphine; Handled+Saline, Figure 2.1B). In contrast to 
the decreased analgesia observed in Handled+Morphine animals on Day 3, morphine produced a 
significant increase in ipsilateral PWL of injured animals on Day 3 as compared to Day 1 
(CFA+Morphine; Injection 1 and Injection 3, Figure 2.1B) indicating lack of tolerance 
development.  
Assessment of morphine tolerance  
Morphine tolerance, assessed on Day 5 using a cumulative dosing paradigm, was only observed 
in non-CFA treated animals. As shown in Figure 2.2, the antinociceptive potency of morphine 
was significantly decreased in both the ipsilateral and contralateral hindpaw of uninjured animals 
that received 3 consecutive days of morphine (Handled+Morphine) as compared with uninjured 
animals that received saline (Handled+Saline; Figures 2.2A and C). Indeed, animals that 
received 3 days of saline reached 100% maximum possible analgesia (MPE) at the 8 mg/kg dose. 
In contrast, 100% MPE was not noted until the 18 mg/kg dose in animals that received 3 prior 
days of morphine. Neither the antinociceptive nor the antihyperalgesic potency of morphine was 
different in CFA+Morphine treated animals as compared with CFA+Saline treated animals 
(Figures 2.2B and D) indicating lack of tolerance development. Indeed, no differences in PWLs 
produced by morphine were noted for all doses tested. Together these data indicate that 
persistent inflammatory pain attenuates the development of tolerance to morphine.  
As glia activation in the spinal cord has been implicated in the development of morphine 
tolerance, the next series of experiments examined if glia were similarly activated within the 
vlPAG, and if persistent inflammatory pain altered their activation.  
Experiment 2: Morphine Tolerance is Associated with Increased Glial Cell Activation in the 
vlPAG 
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Increased activity of astrocytes, as evidenced by an increase in GFAP immunoreactivity, was 
only observed in non-CFA treated animals that received morphine (Handled +Morphine, Figure 
2.3B). A representative example of vlPAG GFAP staining in animals administered 
CFA+Morphine versus Handled+Morphine is shown in Figure 2.3A. Western blots confirmed 
increased activity of astrocytes, as evidenced by an increase in relative band intensity of GFAP/ 
b-actin, was only observed in non-injured animals that received morphine (Handled+Morphine, 
Figure 2.3C).  
Similar to what was noted for astrocytes, microglia activity, as evidenced by OX-42 
immunoreactivity, was significantly increased in animals that received morphine in the absence 
of pain (Handled+Morphine, Figure 2.4B). A representative example of vlPAG OX-42 staining 
in animals administered CFA+Morphine versus Handled+Morphine is shown in Figure 2.4A. A 
trend towards increased activity of microglia, as evidenced by an increase in relative band 
intensity of OX-42/b-actin, was only observed in animals that received morphine in the absence 
of pain (Handled+Morphine, Figure 2.4C); however, it did not reach statistical significance. 
Peripheral inflammation induced by intraplantar CFA did not illicit significant increases in 
vlPAG glial cell activity (Figures 2.3 and 2.4). Importantly, one injection of morphine (5 mg/kg) 
was not sufficient to alter vlPAG GFAP (Figure 2.5A) or OX-42 levels (Figure 2.5B) at 24 hours 
post-morphine. Similarly, no increase in GFAP or OX-42 levels were noted 1 hour post-
morphine  (data not shown). No significant group differences were noted in superior colliculus 
GFAP or OX-42 immunoreactivity (F3,23=2.089, p=0.1295 and F3,19=1.416,p=0.2690, 
respectively) or protein level (F3,28=0.232, p=0.8730 and F3,6=1.822, p=0.2435, respectively), 
indicating that changes in vlPAG glial cell activity are region specific (data not shown).  
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Discussion 
The present experiments tested the hypothesis that vlPAG glial cell activity contributes to 
the development of morphine tolerance. Clinical studies indicate that chronic pain attenuates the 
development of morphine tolerance3,132; however, animal studies have yielded variable results133-
135. Therefore, the impact of persistent inflammatory hyperalgesia on morphine tolerance 
development and glial activation were also investigated. Here we report that (1) short-term daily 
administration of an ED50 dose of morphine was sufficient to induce morphine tolerance; (2) 
persistent inflammatory pain induced by intraplantar CFA significantly attenuated morphine 
tolerance; and (3) increased vlPAG microglia and astrocyte activity was only observed in those 
animals made tolerant to morphine. Together, these data suggest a potential role for vlPAG 
microglia and astrocytes in the development of morphine tolerance, and suggest that persistent 
inflammatory pain attenuates morphine tolerance by inhibiting morphine-induced vlPAG glial 
cell activation.   
Increases in vlPAG microglia and astrocyte activity correlate with the development of morphine 
tolerance 
Many mechanisms have been proposed to account for opioid tolerance, including decoupling, 
internalization and/or down-regulation of m opioid receptors136,137, upregulation of NMDA 
receptor function138-140, down-regulation of glutamate transporters141,142, and production of nitric 
oxide (a known mediator of NMDAR function)85. These mechanisms were all thought to 
implicate some form of ‘neuronal adaptation’85. However, it is becoming increasingly clear that 
activated glia mediate many of these ‘neuronal adaptations’ that contribute to morphine 
tolerance85. Consistent with previous reports, here we find that tolerance to morphine developed 
rapidly in the absence of pain24,44,45. Indeed, one ED50 dose of morphine (5 mg/kg) injected 
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subcutaneously for three days was sufficient to induce behaviorally defined tolerance. Paralleling 
the development of tolerance, GFAP and OX-42 protein levels increased significantly within the 
vlPAG, suggesting the activation of astrocytes and microglia, respectively.  
A large body of evidence has accumulated implicating opioids as activators of spinal astrocytes 
and microglia86,87,89,119. In both mice and rats, morphine increases spinal GFAP and OX-42 
protein levels,107,143  as well as glially derived proinflammatory cytokines74,87. Inhibition of spinal 
glia or cytokine release increases the analgesic efficacy of morphine74,87, and attenuates morphine 
tolerance72,86,91,92,119. Our novel findings in the vlPAG parallel the data from studies of spinal 
cord glia, and indicate that supraspinal glial cell activity may also contribute to the development 
of morphine tolerance.  
Under basal conditions glia survey the environment for pathogens, debris, and regulate ion and 
neurotransmitter levels in the synapse to modulate neuronal excitability89. The activation of glia 
results in the release of excitatory substances that oppose morphine analgesia (e.g., 
proinflammatory cytokines)89. Glial release of cytokines increases with chronicity of morphine 
administration85, making these excitatory substances key players in the development of morphine 
tolerance. Glially-derived cytokine release, particularly tumor necrosis factor alpha (TNFa) and 
interleukin-1 beta (IL-1b), results in increased density and conductance of neuronal AMPA144,145 
and NMDA146 receptors, decreased astrocytic glutamate transporter proteins (GLT-1, GLAST)89, 
and down-regulation of neuronal GABA receptors145. These cytokine-induced changes, among 
others147,148, effectively increase neuronal excitability. Morphine binds to neuronal m opioid 
receptors (MOR) in the vlPAG that are primarily located on GABAergic neurons149-151; MOR 
binding in the vlPAG disinhibits GABAergic PAG-RVM projection neurons152, resulting in the 
net excitation of the PAG-RVM-spinal cord descending pain modulatory circuit. Glial-induced 
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increases in the excitability of vlPAG MOR-containing neurons may act to alter the inhibitory 
properties of morphine, thereby decreasing analgesic efficacy and contributing to the 
development of morphine tolerance. 
Persistent inflammatory pain prevented morphine-induced increases in vlPAG glial cell activity 
and attenuated the development of morphine tolerance 
The results of the present study demonstrate that the presence of persistent pain alters both the 
development of morphine tolerance and morphine-induced vlPAG glial cell activation. The 
finding that persistent peripheral inflammation attenuates morphine tolerance is consistent with 
the clinical literature demonstrating that opioid tolerance is attenuated in chronic pain 
sufferers153-155. Indeed, clinical studies have repeatedly shown that morphine tolerance develops 
most robustly in those individuals consuming morphine in the absence of pain117,118. In the 
present study, male rats given CFA 24 hours before the 3-day morphine administration regimen 
showed significant increases in analgesia to all challenge doses of morphine, as compared with 
non-injured animals. Several factors may contribute to the pain-induced attenuation in morphine 
tolerance. First, morphine, given in conjunction with peripheral inflammation, failed to illicit the 
increases in vlPAG microglia and astrocyte activity observed in non-CFA treated animals given 
morphine. Indeed, peripheral inflammatory pain blocked both morphine tolerance and morphine-
induced glial cell activation within the vlPAG. As glia are not activated, no cytokine release 
would be expected, and, therefore, no net change in neuronal excitability. Alternatively, 
cannabinoids, which are released within the PAG during peripheral pain156, have been shown to 
influence both glial activity and morphine analgesia. Cannabinoid receptors are robustly 
expressed within the vlPAG, with approximately 32% of cannabinoid receptor 1 (CB1) 
expressing neurons also expressing m opioid receptor157. Functionally, intra-PAG administration 
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of a CB1 agonist enhances morphine analgesia158, and systemic administration of cannabinoids, 
along with morphine, leads to the attenuation of morphine tolerance158-160. Endocannabinoids 
also possess potent anti-inflammatory properties161, which would likely block the activation of 
glia. Indeed, systemic administration of the cannabinoid receptor agonist WIN 55,212-2 prevents 
microglia and astrocyte activation, and decreases the release of the proinflammatory cytokines 
interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α in the spinal cord162.  
In the present study, no glia activation was noted following administration of CFA alone. These 
results are in contrast with previous reports that peripheral pain, including CFA163-166, peripheral 
neuropathy71,90,94,127,165,167,168,  formalin169, and spinal nerve ligation170 induce significant glia 
activation within the spinal cord. However, given the roles of the spinal cord and PAG in pain 
facilitation and pain modulation, respectively, it is not entirely surprising that there would be 
differential pain-induced regulation of glial activation in these two sites. Together, these studies 
suggest that inflammation elicits differential glial responses in a CNS region-dependent manner, 
and prevents morphine-induced increases in vlPAG glial cell activity.  
How opioids activate glia 
Opioid hyperalgesia is still observed in neuronal opioid receptor (mu, delta, and kappa) knockout 
mice98, suggesting that the anti-analgesic affects of morphine (e.g., anti-analgesia and tolerance) 
are mediated by non-neuronal opioid receptors. Indeed, it was recently discovered that morphine 
analgesia is modulated not only by classical neuronal opioid receptors but also by non-classical 
glial receptor activity78. Opioids have been shown to bind to Toll-like receptor 4 (TLR4)78, an 
innate immune receptor located on microglia and astrocytes, and an abundance of evidence has 
accumulated indicating that TLR4 activity opposes morphine analgesia78,89. Functionally, 
animals that receive TLR4 antagonism, as well as TLR4 knockout mice, exhibit increased 
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responsiveness to the analgesic properties of acute morphine administration89. Similarly, 
systemic administration of TLR4 antagonists attenuates morphine tolerance78. To date, the 
specific role of TLR4 in morphine tolerance development has not been elucidated. However, 
given our findings that the development of morphine tolerance correlates with increased vlPAG 
glial cell activation, and the evidence showing that TLR4 is expressed on rat PAG glia171,172, 
future studies investigating the potential role of vlPAG TLR4 in the development of morphine 
tolerance are warranted.  
Conclusions 
There is extensive literature supporting a critical role for glial cell activation in the development 
of morphine tolerance. Our findings that increased vlPAG glial activity is concurrent with the 
development of morphine tolerance, and that pain inhibits both vlPAG glial reactivity and 
morphine tolerance development suggests that vlPAG glia play a significant role in the 
development of morphine tolerance. Taken together, our results may provide a direct 
neurobiological mechanism whereby chronic inflammatory pain attenuates the development of 
morphine tolerance, and implicate vlPAG glial cells as key regulators of this phenomenon. 
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Chapter 2 Figures 
 
 
 
Figure 2.1 Summary of results from morphine analgesia testing on day 1 and day 3. 
Contralateral (A) and ipsilateral (B) PWL (in seconds) following intraplantar CFA or handling 
(Baseline), and after the first and third injection of morphine or saline in CFA+Morphine (n=6), 
CFA+Saline (n=7), Handled+Morphine (n=6), and Handled+Saline (n=5) treated male rats. The 
first and third injection of morphine caused an increase in contralateral and ipsilateral PWL as 
compared with saline controls (p< 0.05; A & B, respectively). Contralateral PWL did not differ 
between CFA+Saline and Handled+Saline groups at any time point (p> 0.05; A). CFA treatment 
caused a significant decrease in ipsilateral PWL at all time points as compared with handled 
controls (p< 0.05; CFA+Saline; Handled+Saline; B). While uninjured animals treated with 
morphine showed a decrease in analgesia to the third injection as compared with the first (p< 
0.05; A), CFA treated animals showed an increase in antihyperalgesia to the third injection (p< 
0.05; B). Asterisks indicate significant differences between CFA+Morphine and 
Handled+Morphine groups. 
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Figure 2.2 Summary of results from morphine tolerance testing on day 4. 
PWL (in seconds) as a function of cumulative doses of morphine in handled (A & C), and CFA 
treated (B & D) male rats. Both ipsilateral (A & B) and contralateral (C & D) PWL data are 
presented. Animals received 3 consecutive days of morphine (5 mg/kg; sc, open circles) or saline 
(1 ml/kg; sc, filled circles). CFA+Morphine treated animals (n=7) did not differ from 
CFA+Saline treated animals (n= 4) in response to cumulative morphine on day 5 (ipsilateral; 
F1,9=1.128,p=0.3159 & contralateral; F1,9=1.470,p=0.2563). Handled+Morphine treated animals 
(n= 9) showed a significant decrease in PWL in response to cumulative morphine on day 5 as 
compared with Handled+Saline animals (n=5; ipsilateral; F1,12 =21.702,p=0.0006 & contralateral; 
F1,12=20.373,p=0.0007).  
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Figure 2.3 Summary of vlPAG GFAP protein following morphine tolerance. 
Representative fluorescent photomicrographs of GFAP immunoreactivity in the vlPAG of 
animals treated with CFA+Morphine (a) and Handled+Morphine (b) (A). Densitometry of GFAP 
immunoreactivity in the vlPAG (B).  Administration of morphine, in the absence of CFA 
(Handled+Morphine; n=7), resulted in a significant increase in GFAP immunoreactivity within 
the vlPAG (F3,22=10.022, p=0.0002). No differences in GFAP levels were noted for the 
CFA+Morphine (n=11), CFA+Saline (n=4) or Handled+Saline control groups (n=4). Relative 
band intensity of GFAP/b-actin in the vlPAG (C). Administration of morphine, in the absence of 
CFA (Handled+Morphine; n=5), resulted in a significant increase in relative band intensity of 
GFAP/b-actin in the vlPAG (F3,19=10.256, p=0.0003). No differences in GFAP levels were noted 
for the CFA+Morphine (n=5), CFA+Saline (n=7) or Handled+Saline (n=6) control groups. 
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Figure 2.4 Summary of vlPAG OX-42 following morphine tolerance. 
Representative fluorescent photomicrographs of OX-42 immunoreactivity in the vlPAG of 
animals treated with CFA+Morphine (a) and Handled+Morphine (b) (A). Densitometry of OX-
42 immunoreactivity in the vlPAG (B).  Administration of morphine, in the absence of CFA 
(Handled+Morphine; n=8), significantly increased OX-42 immunoreactivity within the vlPAG 
(F3,19=9.270, p=0.0005). No differences in OX-42 levels were noted for the CFA+Morphine 
(n=7), CFA+Saline (n=4) or Handled+Saline (n=4) control groups. Relative band intensity of 
OX-42/b-actin in the vlPAG (C). Administration of morphine, in the absence of CFA 
(Handled+Morphine; n=5), resulted in an increase in relative band intensity of OX-42/b-actin in 
the vlPAG (F3,10=2.544, p=0.1151); however, it did not reach significance. 
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Figure 2.5 Summary of GFAP and OX-42 protein in the vlPAG following acute 
morphine. 
Densitometry of GFAP (A) and OX-42 (B) immunoreactivity in the vlPAG in 
Handled+Morphine (n=3), CFA+Morphine (n=4), Handled+Saline (n=4), and CFA+Saline (n=5) 
animals 24 hours following one morphine or saline injection. Neither CFA nor morphine (5 
mg/kg, sc) increased vlPAG GFAP (F(3,12)=0.494; p=0.693) or OX-42 (F(3,12)=0.162; p=0.9198) 
levels in the vlPAG as compared to handled and saline controls. 
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 Abstract 
The ventrolateral periaqueductal gray (vlPAG) is an integral locus for morphine action. 
Although it is clear that glia contribute to the development of morphine tolerance, to date, the 
investigation of their role has been limited to spinal and medullary loci. Opioids induce a 
neuroinflammatory response that opposes acute and long-term analgesia, thereby limiting their 
efficacy as therapeutic agents. Recent data suggest that the innate immune receptor Toll-like 
receptor 4 (TLR4), along with its co-receptor myeloid differentiation factor-2 (MD-2), mediates 
these effects. To date, the brain loci through which TLR4 modulates morphine tolerance have not 
been identified. We have previously demonstrated that chronic subcutaneous morphine results in 
tolerance that is accompanied by increases in vlPAG glial cell activity. Using in vivo 
pharmacological manipulations of vlPAG glia and TLR4 in the adult male rat, we show that 
intra-vlPAG administration of the general glial cell metabolic inhibitor propentofylline or the 
astrocyte activity inhibitor fluorocitrate attenuate tolerance to morphine. Characterization of 
MD-2 expression within the PAG revealed dense MD-2 expression throughout the vlPAG. 
Further, antagonizing vlPAG TLR4 dose-dependently prevented the development of morphine 
tolerance, and vlPAG microinjections of TLR4 agonists dose-dependently produced a ‘naïve’ 
tolerance to subsequent challenge doses of morphine. Finally, using a model of persistent 
inflammatory pain and pharmacological manipulation of TLR4 we demonstrate that systemic 
antagonism of TLR4 potentiated acute morphine antihyperalgesia. These results, together, 
indicate that vlPAG glia regulate morphine tolerance development via TLR4 signaling, and 
implicate TLR4 as a potential therapeutic target for the treatment of pain.  
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Introduction 
Opioids remain an integral part of clinical pain management 3. However, acute and 
chronic morphine induces a CNS proinflammatory glial response that actively opposes the 
analgesic effects of morphine, and contributes to the development of tolerance 72,173. Morphine-
induced neuroinflammation is evidenced by increases in spinal microglial and astrocyte activity 
markers OX-42 and glial fibrillary acidic protein (GFAP), respectively143. Release of glially 
derived proinflammatory cytokines, hallmarks of neuroinflammation, is also induced by 
morphine107. Intrathecal glia inhibitors (e.g., propentofylline) decrease morphine-induced 
cytokine release, and attenuate morphine tolerance72,96. Similarly, blockade of spinal cytokine 
action attenuates tolerance, indicating that CNS glia modulate morphine action74,86.  
Opioids, including morphine, bind to myeloid differentiation factor-2 (MD-2) of the 
innate immune receptor toll-like receptor 4 (TLR4), leading to initiation of the TLR4 signaling 
cascade that results in a proinflammatory response75,79. TLR4 is found primarily on microglia, 
and to a lesser degree on astrocytes99,100. Spinal TLR4 activity opposes the acute effects of 
morphine, including antinociception, and contributes to opioid-induced hyperalgesia78,79. Unlike 
classical opioid receptors, which only bind the (-)-stereoisomer of opioids, TLR4 binds opioids 
in a non-stereoselective fashion with both (-)- and (+)-ligands affecting the signaling cascade and 
modulating opioid analgesia78. Indeed, (+)-morphine decreases acute intrathecal (-)-morphine 
analgesia174. Similarly, in vitro studies show that both (-) and (+)-naloxone block (-)-morphine-
induced TLR4 activation78. Although systemic antagonism of TLR4 prevents the development of 
tolerance to systemic morphine, the brain loci through which TLR4 mediates morphine tolerance 
have not been investigated78.  
37 
The PAG, and its descending projections to the rostral ventromedial medulla (RVM) and 
spinal cord, comprises an essential neural circuit for opioid-mediated analgesia175. Tolerance is 
quick to develop following repeated administration of morphine into the ventrolateral PAG 
(vlPAG)49. Blocking opioid binding in the vlPAG with the antagonist naltrexone significantly 
attenuates the development of tolerance to systemically administered morphine, indicating that 
key mechanisms underlying morphine tolerance are localized in the vlPAG24.  
Although it is clear that CNS activation of glia contribute to the development of 
morphine tolerance, no studies to date have examined the role of activated glia within the PAG, 
despite extensive evidence indicating its importance for morphine action45,49,50. 
Here we tested the hypothesis that vlPAG glia activation contributes to morphine 
tolerance development through action at TLR4. As morphine is primarily consumed for the 
alleviation of severe pain, in our final experiments we used an animal model of persistent 
inflammatory pain to test the hypothesis that TLR4 blockade would enhance the antihyperalgesia 
effects of acute morphine.  
Materials and Methods 
Subjects 
Weight-matched (250-350g) male Sprague Dawley rats (Charles River; Wilmington, MA) were 
pair-housed on a 12:12 hour light:dark cycle (lights on a 7:00 am). Access to food and water was 
available ad libitum throughout the experiments except during behavioral testing. All studies 
were approved by the Institutional Animal Care and Use Committee (IACUC) at Georgia State 
University, and performed in strict compliance with Ethical Issues of the International 
Association for the Study of Pain (IASP) and National Institute of Health (NIH). All efforts were 
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made to reduce the number of animals used in these experiments and to minimize any possible 
suffering by the animal. 
Intra-vlPAG Cannulae Implantation 
Animals in experiments 1, 2.2, & 2.3 were anesthetized to a deep surgical plane with 5% 
Isoflurane (Baxter Healthcare Corporation; Deerfield, IL) and maintained at 2-5% Isoflurane 
throughout surgery. Animals were implanted with bilateral guide cannulae (22 gauge; Plastics 
One; Roanoke, VA) aimed at the ventrolateral PAG (AP:  1.7 mm, ML: + 0.6 mm, DV: -5.0 mm 
from lambda) using stereotaxic techniques as previously described114. Skull screws and dental 
acrylic were applied to hold cannulae securely in place. Skin staples were used to close the site, 
and animals were given 0.05 ml Baytril (sc) to prevent infection. Injection cannulae were 
inserted into guide cannulae once every 24 hours to acclimate the animals to the injection 
procedure and maintain cannulae patency. As repeated insertion of the injection cannulae has the 
potential to cause tissue damage-induced glial activation, we compared OX-42 and GFAP 
staining levels in the vlPAG for animals treated with vlPAG saline and animals that were treated 
with sc saline 173 and found no differences in expression (data not shown).  
Experiment 1.1: Influence of vlPAG glial cell activation on morphine tolerance development 
Following recovery from cannulae implantation (1 week) animals were given morphine (5 
mg/kg; sc, NIDA; Bethesda, MD) once a day for three days to induce behavioral tolerance to 
challenge doses of morphine. The 5 mg/kg dose was chosen based on our previous studies 
demonstrating this to be the 50% effective dose (ED50) for systemic morphine in male rats 
122,124,125. The time course of morphine injection was chosen based on our previous data 
demonstrating this to be sufficient for the induction of morphine tolerance 45,173. Control animals 
received sterile saline (1 ml/kg; sc) once a day for three days.  
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Glia Inhibition 
Separate groups of animals were treated with one of 3 glia inhibitors: the general glial cell 
inhibitor propentofylline (10 fmol or 100 fmol, SIGMA; St. Louis, MO), the microglia inhibitor 
minocycline (10 fmol, 1 pmol or 10 pmol; SIGMA), or the astrocyte inhibitor fluorocitrate (1 
fmol or 10 pmol; SIGMA). Glia inhibitors were administered 16 hrs. and 1 hr. prior to the first 
morphine injection and 30 min. prior to the last two morphine injections based on the injection 
protocols of Cui, Wei, Tawfik and colleagues 95,96,176. Previous studies suggest that preemptive 
doses (i.e., the 16 and 1 hour doses) of these inhibitors are necessary to counteract morphine-
induced glial cell activation 95,176. The 30-minute time point was chosen based on previous work 
using minocycline 96. All doses were chosen based on intracranial doses known to affect glia 
without affecting neurons, and known to have no effect on the microglia and astrocyte activity of 
naïve animals 176. All drugs were administered bilaterally (0.25 ml/ side/ 2min). Control animals 
received intra-vlPAG microinjections of vehicle (sterile saline; 0.25 µl/side). Microinjections 
were slowly infused through a 5 ml Hamilton Syringe at a rate of 0.125 ml/minute using a 
Harvard Apparatus 11 Plus Syringe Pump (Holliston, MA) to allow for diffusion of the drug and 
to minimize tissue damage. Injection cannulae were left in place for 60 seconds following the 
microinjections to prevent backflow upon removal.  
Morphine challenge 
Tolerance was assessed on day 5 (day 1 being the first day of vlPAG microinfusions) by 
injecting cumulative doses of morphine every 20 min, resulting in doses of 3.2, 5.6, 8.0, and 10.0 
mg/kg (sc) as previously described 45,173.  Nociception was assessed using the paw thermal 
stimulator 15 min after each injection122,126.  Briefly, for this test, the rat is placed in a clear 
Plexiglas box resting on an elevated glass plate maintained at 30oC. A radiant beam of light is 
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positioned under the hindpaw and the time for the rat to remove the paw from the thermal 
stimulus is electronically recorded as the paw withdrawal latency (PWL). A maximal PWL of 
20.48 seconds was used to prevent excess tissue damage due to repeated application of the 
noxious thermal stimulus. Animals were acclimated to the testing apparatus (30 minutes a day 
for 3 consecutive days) at the start of the experiment. All behavioral testing took place between 
12:00 pm and 5:00 pm (lights on at 7:00 am). All testing was conducted blind with respect to 
group assignment. 
Data Analysis and Presentation 
PWLs are measured in seconds and the half-maximal antinociceptive effect (D50) and 95% 
confidence intervals (CI) were calculated from dose-response curves generated using GraphPad 
software 43,45. The lower limit for calculating D50 values was the mean baseline score, and the 
upper limit was the mean paw withdrawal latency (PWL) following administration of the highest 
morphine dose. Changes in D50 between groups were assessed using ANOVA, and Fisher’s post-
hoc tests were used to determine specific group differences when a significant main effect was 
observed. All values are reported as Mean D50 + 95% CI; p<0.050 was considered significant.  
Experiment 1.2: Anatomical Assessment of vlPAG Glial Cell Inhibition 
One hour following tolerance assessment, animals were given a lethal dose of Nembutal (160 
mg/kg; i.p.) and transcardially perfused with 250 ml of 0.9% sodium chloride containing 2% 
sodium nitrite as a vasodilator to remove blood from the brain. Immediately following blood 
removal, 300 ml of 4% paraformaldehyde in 0.1 M phosphate buffer containing 2.5% acrolein 
(Polysciences Inc.; Warrington, PA) was perfused through the brain as a fixative. A final rinse 
with 250 ml of sodium chloride/sodium nitrite solution was perfused through the brain to remove 
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any residual acrolein. Brains were removed and placed in a 30% sucrose solution and stored at 
4°C until sectioning.  
Cannulae Placement Verification 
Perfusion fixed brains were sectioned into 25 µm coronal sections with a Leica 2000R freezing 
microtome and stored free-floating in cryoprotectant-antifreeze solution at -20°C. A 1:6 series 
through the rostocaudal axis of each brain was Nissl stained, coverslipped, and cannulae 
placement was verified visually using a Nikon microscope (10X magnification). Animals with 
bilateral cannulae located outside of the vlPAG (e.g., deep mesencephalic nucleus (DpMe)) were 
considered “cannulae misses” and were included for analysis for site specificity. 
Immunohistochemistry 
As a positive control that propentofylline, minocycline, and fluorocitrate inhibited microglial and 
astrocyte activity, immunoreactivity of vlPAG glial cell activity markers were analyzed. 
Hallmarks of glial cell activity include increased cytokine release that correlates with increased 
expression of the protein markers CD-11b (OX-42; microglia), and glial fibrillary acidic protein 
(GFAP; astrocytes) 86. Further, increased glial cell activity is evidenced by a profound shift in 
morphology that can be easily visualized using immunohistochemistry for OX-42 and GFAP 127. 
Perfused brains were sectioned into 25 µm coronal sections with a Leica 2000R freezing 
microtome and stored free-floating in cryoprotectant-antifreeze solution 128 at -20°C. A 1:6 series 
through the rostrocaudal axis of each brain was processed for OX-42 and GFAP 
immunoreactivity using standard immunohistochemical techniques 129. Briefly, sections were 
rinsed extensively in potassium phosphate-buffered saline (KPBS) immediately followed by a 
20-minute incubation in 1% sodium borohydride. The tissue was then incubated in primary 
antibody solution (mouse anti-CD11b (OX-42) 1:3000, Serotec; Raleigh, NC or rabbit anti-
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GFAP 1:5,000; Abcam; Cambridge, MA) in KPBS containing 1.0% Triton-X for one hour at 
room temperature followed by 48 hours at 4°C. After rinsing with KPBS, the tissue was 
incubated for one hour in secondary antibody (biotinylated IgG goat anti-mouse or anti-rabbit; 
1:600, Jackson ImmunoResearch; West Grove, PA), rinsed with KPBS, and then incubated for 
one hour in an avidin-biotin peroxidase complex (1:10; ABC Elite Kit; Vector Labs; Burlingame, 
CA). After rinsing in KPBS and sodium acetate (0.175 M; pH 6.5), OX-42 or GFAP 
immunoreactivity was visualized as a black reaction product using nickel sulfate intensified 3,3’-
diaminobenzidine (DAB) solution (2 mg/10 ml) containing 0.08% hydrogen peroxide in sodium 
acetate buffer. After 15 minutes, tissue was rinsed in sodium acetate buffer followed by KPBS. 
Following secondary incubation, sections were rinsed in KPBS. Sections were mounted out of 
KPBS onto gelatin-subbed slides, air-dried and dehydrated in a series of graded alcohols. Tissue-
mounted slides were then cleared in Xylenes and glass cover-slipped using Permount.  
Anatomical data analysis and presentation 
Levels of OX-42 and GFAP immunoreactivity in the vlPAG were compared across treatment 
groups using semi-quantitative densitometry as previously described 45,131,173. 12-bit grayscale 
images that included the region of interest (ROI) were captured using QImaging Retiga EXi 
CCD camera (Surrey, BC, Canada) attached to a Nikon microscope and iVision Image analysis 
software (Biovision Technologies; Exton, PA). Grayscale values for each image were inverted so 
that higher values were representative of increased staining levels. Images of three slices through 
each ROI for each animal were analyzed and data sampled unilaterally. Data sampling occurred 
by using the drawing tools in iVision to outline the ROI and using the “measure” function to 
determine an average grayscale pixel value for the outlined area. ROI measures were corrected 
for nonspecific binding by subtraction of background measure taken from gray matter adjacent to 
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the ROI.  Data were analyzed across 3 representative levels through the rostral-caudal axis of the 
vlPAG (Bregma -7.08, -7.68, and -8.30) as previously described 45,130. Densitometry values are 
presented as the mean + S.E.M. density of immunoreactivity. Data were analyzed using an 
ANOVA to determine significant main effects of treatment. Fisher’s post hoc tests were used to 
determine specific group differences when a significant main effect was observed; p < 0.050 was 
considered statistically significant.  
Experiment 2:  Modulation of Morphine Tolerance by vlPAG TLR4 
The TLR4/MD-2 complex binds opioids including morphine and mediates glial cell activation 
73,78,79,89. While TLR4 signaling has been implicated in glially-mediated morphine opposition, the 
specific role of TLR4 activation in the development of morphine tolerance is largely unknown. 
Our overarching hypothesis is that morphine activation of TLR4 within the vlPAG is a primary 
mechanism underlying the development of tolerance. 
Experiment 2.1: Myeloid Differentiation Factor-2 expression within the PAG 
Immunohistochemistry 
Normal male Sprague Dawley rats were perfused as described above. A 1:6 series through the 
rostral caudal axis (Bregma -6.72, -7.08, -7.68, -8.04, -8.28, and -8.76) of the PAG was 
processed for immunohistochemical labeling of MD-2 as a positive control for the presence of 
the MD-2/TLR4 complex. Both the dorsolateral (dlPAG) and vlPAG were examined. The dlPAG 
(Bregma -6.72, -7.08, -7.68, and -8.04) was included as this region is virtually devoid of the mu 
opioid receptor (MOR), expresses very little morphine-induced Fos, and has not been implicated 
in morphine tolerance development 51,125. Immunohistochemistry is as described above with the 
exception of the primary (rabbit anti-MD-2 primary antibody; 1:200; Abcam) and secondary  
(biotinylated IgG goat anti-rabbit secondary; 1:600, Jackson ImmunoResearch) antibodies.  
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Twelve-bit grayscale images that included the region of interest (ROI) were captured using a 
QImaging Retiga EXi CCD camera and iVision Image analysis software to visualize MD-2 
expression within the PAG. Anatomical data analysis and presentation are as described above, 
except here we sampled 2 sections per animal per Bregma level. 
Experiment 2.2: Necessity of vlPAG TLR4 in morphine tolerance development 
Following recovery from cannulae implantation (1 week) animals were given morphine (5 
mg/kg; sc; NIDA) once a day for three consecutive days to induce behavioral tolerance to a 
challenge dose of morphine. Control animals received saline (1 ml/kg; sc) once a day for three 
consecutive days. Immediately following sc injections, animals received bilateral intra-vlPAG 
microinjections of the competitive TLR4 antagonist LPS-RS (1.7 µg or 2.4 µg /0.5 µl/side; 
Invivogen; San Diego, CA), the stereoselective TLR4 antagonist (+)-naloxone (5 µg/0.5 µl/side; 
NIDA) or saline (0.5 µl/side; as a vehicle control). LPS-RS (produced by R. sphaeroides) was 
chosen as a TLR4 antagonist as it has been shown to competitively bind to TLR4, enhance 
morphine analgesia, prevent release of cytokines, and block the morphine-induced TLR4 
signaling cascade 89. The LPS-RS dose was chosen based on intracranial LPS doses, and the fact 
that LPS and LPS-RS are typically administered at the same dose 78,177-180.  (+)-naloxone was 
chosen as this TLR4 antagonist readily crosses the blood brain barrier, and has been shown to 
enhance morphine analgesia and block the morphine-induced TLR4 signaling cascade 78,89,181. 
The (+)-naloxone dose was chosen based on intra-PAG doses of (-)-naloxone and the fact that (-
)- and (+)-naloxone block (-)-morphine-induced TLR4 signaling to a similar degree, and on a 
similar time course 78,182. Tolerance assessment took place 24 hours following 3 days of drug 
administration as described above. Briefly, animals were given cumulative doses of sc morphine 
in the absence of intra-vlPAG microinjections and PWLs were measured in response to a 
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noxious thermal stimulus. Following tolerance assessment animals were perfused and brains 
removed and sectioned for visualization of cannulae location. To determine site specificity, 
animals with bilateral cannulae located outside of the vlPAG (e.g., DpMe) were included in the 
analysis. Data analysis and presentation are as described above. 
Experiment 2.3: Sufficiency of vlPAG TLR4 activation to induce ‘naïve’ tolerance to morphine 
Experimental methods are identical to Experiment 2.2. To test for the sufficiency of vlPAG 
TLR4 to induce tolerance, a separate group of animals received bilateral intra-vlPAG injections 
of the prototypical TLR4 agonist LPS (1.7 µg or 5 µg /0.5 µl/side; Sigma, St. Louis, MO), the 
TLR4 agonist KDO2 (0.5 µg, 1 µg, or 5µg/0.5µl/side; Avanti Polar Lipids), the stereoselective 
TLR4 agonist (+)-morphine (5 µg/0.5 µl/side; NIDA), or vehicle control (saline; 0.5 µl/side) 
once a day for three consecutive days. Animals in this experiment did not receive sc (-)-
morphine until the final testing day (morphine challenge). LPS is a prototypical TLR4 agonist 
and has been shown to competitively bind to TLR4, resulting in the production of cytokines, and 
attenuation of acute morphine analgesia 78. The chosen LPS dose was based on intracranial LPS 
doses that are sufficient to induce glial activation and cytokine expression 177-180. Similar doses 
of KDO2-Lipid A were chosen because KDO2 is a substructure of LPS with endotoxin activity 
that is equal to that of native LPS. Finally, the (+)-morphine dose was chosen based on vlPAG 
doses of (-)-morphine, and the fact that (+)- and (-)-morphine activate the TLR4 signaling 
cascade to a similar degree in vitro 24,78. Twenty-four hours following intra-vlPAG injections of 
TLR4 agonists, animals were given cumulative challenge doses of sc morphine and PWLs were 
tested to assess tolerance development as described above. Data analysis and presentation are as 
described above. 
Experiment 3: Influence of TLR4 on acute morphine antihyperalgesia 
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Morphine is primarily consumed for the alleviation of severe pain, and chronic morphine use is 
associated with tolerance development. Therefore, our final series of experiments were 
conducted to determine if blockade of vlPAG TLR4 with (+)-naloxone would potentiate the 
antihyperalgesic effect of morphine in a model of persistent inflammatory pain. 
Persistent Inflammatory Hyperalgesia 
In a separate group of animals, persistent inflammatory hyperalgesia was induced by injection of 
complete Freund’s adjuvant (CFA; 200 µl; Sigma; St. Louis, MO), suspended in an oil/saline 
(1:1) emulsion, into the plantar surface of the right hindpaw as previously described 45,122,123. 
Twenty-four hours following intraplantar CFA injection, acute antihyperalgesia was measured 
by injecting cumulative doses of morphine every 20 min, resulting in doses of 3.2, 5.6, 8.0, and 
10.0 and 18.0 mg/kg (sc; NIDA). Hyperalgesia was assessed using the paw thermal stimulator at 
baseline, and 15 min after each injection, as described above 122,126. Animals received one sc 
injection of (+)-naloxone (8 mg/kg, sc; NIDA) or saline (1 ml/kg, sc) with the first dose of 
morphine to produce 2 treatment groups ((+)-Naloxone/Morphine; Vehicle/Morphine). A 
separate group of animals received repeated injections of saline on the same time-course as the 
cumulative morphine doses to determine if (+)-naloxone induces antihyperalgesia in the absence 
of morphine ((+)-Naloxone/Vehicle). The 8 mg/kg dose of (+)-naloxone was chosen based on 
previous studies demonstrating it to be sufficient to potentiate acute morphine analgesia in the 
absence of pain 78. Animals were acclimated to the testing apparatus (30 minutes a day for 3 
consecutive days) at the start of the experiment. All behavioral testing took place between 
12:00pm and 5:00pm (lights on at 7:00am). All testing was conducted blind with respect to 
group assignment. Data analysis and presentation are as described above. 
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Results 
Experiment 1: Inhibition of vlPAG Microglia and Astrocyte Activity Attenuated Morphine 
Tolerance: vlPAG infusions of propentofylline attenuated morphine tolerance.  
Administration of cumulative doses of morphine produced an increase in paw withdrawal latency 
(PWL) in all animals tested (Figure 3.1A). An analysis of variance revealed a significant main 
effect of treatment (F(4,27) = 7.84; p = 0.0002), with the antinociceptive potency of morphine 
being greatest in rats pretreated with vlPAG Vehicle + sc Saline for 3 days (D50 = 2.499 mg/kg, 
CI = 1.917 - 3.081). In contrast, pretreatment with vlPAG Saline + sc Morphine resulted in a 
significant 4-fold rightward shift in the dose-response curve (D50 = 10.64 mg/kg, CI = 7.636 - 
13.65; p = 0.0004), indicating tolerance to morphine. Intra vlPAG pretreatment with 100 fmol of 
propentofylline significantly increased the antinociceptive potency of morphine (D50  =  5.48 
mg/kg, CI = 3.503 - 7.464) as compared with animals made tolerant to morphine (vlPAG Vehicle 
+ sc Morphine; p=0.0054). However, the D50 for these animals was significantly increased as 
compared with saline controls (vlPAG Vehicle + sc Saline; p = 0.030), indicating an attenuation, 
but not elimination, of tolerance. 10 fmol of propentofylline significantly increased the 
antinociceptive potency of morphine (D50  =  4.02 mg/kg, CI = 2.203 – 5.787) as compared with 
animals made tolerant to morphine (Vehicle + sc Morphine; p=0.0046). Indeed, animals treated 
with 10fmol propentofylline did not differ from saline controls (vlPAG Vehicle + sc Saline; p= 
0.054) indicating a complete abolishment of tolerance. Animals pretreated with 10fmol 
propentofylline in the absence of morphine (vlPAG PPF + sc Saline; D50  =  4.318 mg/kg, CI = 
1.730 – 6.905, n = 3) did not differ from vehicle controls (vlPAG Vehicle + sc Saline; p = 
0.0796, data not shown) indicating that chronic pretreatment with propentofylline alone does not 
potentiate morphine analgesia. Additionally, these effects were site specific as animals treated 
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with 10fmol propentofylline outside of the PAG (cannulae misses; n=5) and sc morphine (D50 = 
11.53, CI = 6.633 - 16.43) significantly differed from animals treated with vlPAG Vehicle + sc 
Saline (p = 0.0012), and did not differ from vlPAG Vehicle + sc Morphine treated animals (p = 
0.735, data not shown). Together, these results indicate that propentofylline is sufficient to 
attenuate the development of tolerance to sc morphine, and suggest that glial cell activity in the 
vlPAG contributes to the development of morphine tolerance. 
Inhibition of vlPAG microglia activity with minocycline was not sufficient to attenuate morphine 
tolerance.  
Morphine tolerance, assessed using a cumulative dosing paradigm, was observed in all groups 
that received sc morphine once a day for 3 days (Figure 3.1B). An analysis of variance of the 
data indicated a significant main effect of treatment (F(4,34) = 8.82; p < 0.0001). Post-hoc analysis 
revealed that the antinociceptive potency of morphine was significantly decreased in animals that 
received 3 days of vlPAG Vehicle + sc Morphine (D50 = 10.13 mg/kg, CI = 6.991 – 13.27) as 
compared with animals that received 3 days of vlPAG Vehicle + sc Saline (D50 = 2.37 mg/kg, CI 
= 1.793 – 2.938), indicating tolerance to morphine (p = 0.0006). Animals that received intra-
PAG injections of the microglial cell activity inhibitor minocycline had D50s that did not differ 
from animals made tolerant to morphine (10fmol: D50 = 10.35 mg/kg, CI = 9.185 – 11.51, p = 
0.445; 1pmol: D50 = 8.67 mg/kg, CI = 6.882 – 10.46, p = 0.196; 10pmol: D50 = 10.03 mg/kg, CI 
= 8.031 – 12.02, p = 0.483). Additionally, all animals treated with minocycline had D50s that 
were significantly greater than animals treated with vlPAG Vehicle + sc Saline (10fmol: p < 
0.0001; 1pmol: p < 0.0001; 10pmol: p < 0.0001) indicating tolerance to morphine. These results 
indicate that blockade of vlPAG microglial cell activity is not sufficient to attenuate the 
development of morphine tolerance.  
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Inhibition of vlPAG astrocyte activation with fluorocitrate attenuated morphine tolerance.  
Administration of cumulative doses of morphine produced an increase in paw withdrawal latency 
(PWL) in all animals tested (Figure 3.1C). An analysis of variance indicated a significant main 
effect of treatment (F(3,22) = 10.50; p = 0.0002). Morphine antinociception was significantly 
decreased in animals that received vlPAG Vehicle + sc Morphine (D50 = 10.44 mg/kg, CI = 
7.488 – 13.39) as compared with animals that received vlPAG Vehicle + sc Saline (D50 = 2.39 
mg/kg, CI = 1.817 – 2.966), indicating tolerance to morphine (p = 0.0004). 1 fmol and 10 pmol 
of the astrocyte activity inhibitor fluorocitrate attenuated tolerance to morphine as compared with 
animals treated with vlPAG Vehicle + sc Morphine (1fmol: D50 = 5.61 mg/kg, CI = 4.406 – 
6.819, p = 0.018; 10pmol: D50 = 6.36 mg/kg, CI = 5.337 – 7.381, p = 0.023). However, animals 
treated with fluorocitrate showed a significant rightward shift in the dose-response curve as 
compared with animals treated with vlPAG Vehicle + sc Saline (1fmol: p = 0.0003; 10pmol: p 
<0.0001). These results indicate that fluorocitrate is sufficient to attenuate, but not eliminate, the 
development of morphine tolerance, and suggests that vlPAG astrocyte activity contributes to the 
development of morphine tolerance.  
Experiment 1.2: Anatomical Assessment of vlPAG Glial Cell Inhibition  
To assess the efficacy of the metabolic glial inhibitors administered, immunohistochemistry, in 
combination with densitometry, was used to measure microglia and astrocyte activity within the 
PAG. In agreement with our previous findings, subcutaneous injections of morphine once daily 
for three days significantly increased vlPAG microglia activity as evidenced by an increase in 
OX-42 immunoreactivity (Figure 3.2A) in comparison to saline controls (F(8,19) = 6.54; p = 
0.002) 173. vlPAG microinfusions of the microglial cell metabolic inhibitor minocycline at 10 
fmol, 1 pmol, and 10 pmol concentrations significantly decreased microglia (p = 0.0008, 0.0002, 
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and p < 0.0001, respectively; Figure 3.2A), but not astrocyte activity (p=0.15, 0.36, and 0.25, 
respectively; data not shown), compared with animals treated with vlPAG Vehicle + sc 
Morphine.  The effect was dose-dependent with the highest concentration of minocycline being 
most effective at decreasing morphine-induced microglial cell activation. These results confirm 
that minocycline specifically inhibited microglia, and not astrocytes, and suggest that 
minocycline’s inability to attenuate morphine tolerance was not due to insufficient microglia 
inhibition by our drug infusions. 
Similar to what was noted for microglia, and in agreement with our previous findings, chronic 
subcutaneous morphine significantly increased vlPAG astrocyte activity, as evidenced by an 
increase in GFAP immunoreactivity  (Figure 3.2B) as compared with saline controls (F(8,17) = 
7.14; p = 0.038) 173. vlPAG microinfusions of the astrocyte metabolic inhibitor fluorocitrate (1 
fmol & 10 pmol) dose dependently decreased astrocyte (p= 0.059 and 0.0001, respectively; 
Figure 3.2B) but not microglia activity (p= 0.11 and 0.56, respectively; data not shown), in the 
vlPAG as compared with animals treated with vlPAG Vehicle + sc Morphine. This effect was 
dose-dependent such that only the 10 pmol dose significantly decreased morphine-induced 
astrocyte activation. These results confirm that fluorocitrate was specifically targeting astrocytes, 
and not microglia. 
Finally, vlPAG microinfusions of the general glial cell metabolic inhibitor propentofylline (10 
fmol and 100 fmol) significantly decreased morphine-induced activation of microglia and 
astrocytes, as evidence by reduced vlPAG expression of OX-42 (Figure 3.2A; p = 0.002 and 
0.0002, respectively) and GFAP (Figure 3.2B; p = 0.0003 and 0.0005, respectively) compared 
with animals treated with vlPAG Vehicle + sc Morphine. These results indicate that 
administration of propentofylline inhibits morphine-induced activation of both microglia and 
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astrocytes, and together with our behavioral data, indicate that concurrent blockade of both 
microglia and astrocytes was sufficient to attenuate the development of tolerance to morphine.  
Experiment 2: vlPAG TLR4 was Both Necessary and Sufficient for the Development of Morphine 
Tolerance 
Results from Experiment 1 indicate that both microglia and astrocyte activity within the vlPAG 
increase in response to chronic morphine administration, and that blockade of microglia and 
astrocyte, or just astrocyte activation, attenuates the development of morphine tolerance. To 
investigate the mechanism by which morphine affects glia and contributes to tolerance, we 
characterized MD-2 expression in the dlPAG and vlPAG, and tested the hypothesis that 
morphine-induced activation of TLR4 within the vlPAG mediates morphine tolerance 
development.  
Experiment 2.1: dlPAG and vlPAG Localization of MD-2  
In these studies, immunohistochemistry was used to characterize MD-2 expression within the 
vlPAG. The dlPAG, a region not implicated in morphine tolerance development 51, was also 
examined. As indicated in the photomicrograph (Figure 3.3A; inset), MD-2 is present and 
densely expressed within the vlPAG. This region of the PAG contains a high density of mu 
opioid receptors (MOR) 22,114,150,183-186. A comparison of vlPAG (Bregma -6.72 through -8.76) 
and dlPAG (Bregma -6.72 through -8.04; Figure 3A) revealed significantly greater MD-2 
immunoreactivity in the vlPAG as compared with the dlPAG (F(4,1) = 11.275; p = 0.0284). MD-2 
expression was homogeneous across levels of the vlPAG (F(3,5) = 2.702; p = 0.062) and dlPAG 
(F(4,3) = 1.413; p = 0.2872; Figure 3.3B). Post-hoc analysis revealed significantly greater MD-2 
immunoreactivity in the vlPAG as compared with the dlPAG at both rostral (Bregma -6.72; p = 
0.0458) and caudal (Bregma -8.04; p = 0.0380) levels (Figure 3.3B).  
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Experiment 2.2: Antagonism of vlPAG TLR4 with LPS-RS or  (+)-naloxone attenuated the 
development of morphine tolerance.  
An analysis of variance of the data indicated a significant main effect of treatment (F(3,22)=5.35; 
p=0.0064; Figure 3.4A). The antinociceptive potency of morphine was significantly decreased in 
animals that received 3 days of morphine (s.c.; 5 mg/kg) and intra-vlPAG saline (D50 = 10.86 
mg/kg, CI = 7.463 – 14.26) as compared with animals that received 3 days of saline (1ml/kg) and 
intra-vlPAG vehicle (D50 = 6.03 mg/kg, CI = 5.216 – 6.835; p = 0.0051), indicating tolerance to 
morphine (Figure 3.4A). vlPAG microinjections of the TLR4 antagonist LPS-RS dose-
dependently eliminated the development of morphine tolerance. The antinociceptive potency of 
morphine was significantly increased in animals treated with 2.4 µg of LPS-RS (D50 = 4.501 
mg/kg, CI = 3.398 – 5.605) as compared with animals made tolerant to morphine (p = 0.0031) 
indicating blockade of tolerance. These results were limited to the vlPAG as the D50 for animals 
treated with 2.4 mg LPS-RS into misplaced cannulae (cannulae misses, D50 = 8.237, CI = 7.320 – 
11.15) did not differ from vehicle controls (vlPAG Vehicle + sc Morphine, p = 0.4555; data not 
shown). No significant difference in D50 was noted in animals treated with 1.7 mg of LPS-RS 
(D50 = 11.54 mg/kg, CI = 5.447 – 17.62) as compared with the vlPAG Vehicle + sc Morphine 
group (p = 0.4168). These results indicate that vlPAG TLR4 is necessary for the development of 
morphine tolerance. 
The mu opioid receptor (MOR) is stereoselective such that only the (-)-stereoisomers of opioids 
bind. Conversely, opioid agonists and antagonists (e.g., naloxone) affect TLR4 in a non-
stereoselective fashion, with both (-)- and (+)-stereoisomers affecting the signaling cascade in a 
manner that maintains their agonistic and antagonistic properties 77,78.  
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The antinociceptive potency of morphine was significantly decreased (F(3,21) = 8.968; p = 0.0005; 
Figure 3.4B) in animals that received 3 days of morphine (s.c.; 5 mg/kg) and intra-vlPAG saline 
(D50 = 10.75 mg/kg, CI = 7.274 – 14.23) as compared with animals that received 3 days of saline 
(s.c; 1ml/kg) and intra-vlPAG vehicle (D50 = 5.801 mg/kg, CI = 5.002 – 6.600; p = 0.0050) 
indicating tolerance to morphine (1.8-fold rightward shift in the dose-response curve). Similar to 
what was observed for LPS-RS, antagonism of TLR4 with (+)-naloxone (5 µg/0.5 µl) abolished 
the development of morphine tolerance. The antinociceptive potency of morphine was 
significantly increased in animals treated with (+)-naloxone (D50 = 3.529 mg/kg, CI = 2.344 – 
4.715), as compared with animals treated with vlPAG Vehicle + sc Morphine (p=0.0101; Figure 
3.4B). (+)-naloxone also resulted in a significant leftward shift in the dose-response curve as 
compared with the vlPAG Vehicle+sc Saline group (p = 0.0056). However, (+)-naloxone 
pretreatment in the absence of morphine was without effect. Indeed, the D50 for the vlPAG (+)-
naloxone+ sc Saline group (D50 = 6.315mg/kg, CI = 5.440 – 6.830) did not differ from the 
vlPAG Vehicle+sc Saline group (p = 0.5979), indicating that vlPAG TLR4 inhibition does not 
affect antinociception in the absence of morphine, and suggesting that TLR4 is not constitutively 
activated. These results further support our hypothesis that vlPAG TLR4 is necessary for the 
development of morphine tolerance.  
Experiment 2.3:  Activation of vlPAG TLR4 with LPS, KDO2, or  (+)-morphine induced ‘naïve’ 
tolerance. 
Intra-vlPAG microinjections of the TLR4 agonist LPS dose-dependently induced tolerance to 
morphine (F(3,24) = 6.190; p = 0.0029; Figure 3.5A). Indeed rats pretreated with vlPAG LPS (5 
µg) alone (D50 = 9.113 mg/kg, CI = 8.052 – 10.170) did not differ from rats given morphine once 
a day for three days (D50 = 10.81 mg/kg, CI = 7.354 – 14.260; p = 0.1958), indicating ‘naïve’ 
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tolerance to morphine. Additionally, rats pretreated with vlPAG LPS (5 µg) or rats treated with 
vlPAG Vehicle + sc Morphine showed significant decreases in the antinociceptive potency of 
morphine (p = 0.0001 and p = 0.0050, respectively) as compared with rats treated with vlPAG 
Vehicle (D50 = 5.896 mg/kg, CI = 5.093 – 6.700). The lowest dose of LPS (1.7 µg; D50 = 6.462 
mg/kg, CI = 5.439 – 7.485) was without effect (i.e. these animals did not show signs of tolerance 
as compared with vehicle controls (p = 0.1936)). These results indicate that vlPAG TLR4 
agonism is sufficient to induce the development of morphine tolerance.  
Similar to what was noted for LPS, intra-vlPAG microinjections of the TLR4 agonist KDO2 
dose-dependently reduced the antinociceptive potency of morphine (F(4,26)=4.659; p=0.0057; 
Figure 3.5B) with the 5 µg dose having the most robust effect. The antinociceptive potency of 
morphine did not differ in animals pretreated with 5 µg of KDO2 (D50 =7.922 mg/kg, CI = 6.391 
– 9.453) as compared with morphine-pretreated animals (D50 =10.84 mg/kg, CI = 7.415 – 
14.260; p = 0.0816) indicating the development of ‘naïve’ tolerance. Indeed, both KDO2 (5mg) 
and morphine pretreatment caused a significant rightward shift in the morphine dose-response 
curve (p = 0.0044 and p = 0.0015, respectively) as compared with saline controls (D50 = 5.720 
mg/kg, CI = 5.024 – 6.416).  
Intra-vlPAG administration of the TLR4 stereoselective agonist (+)-morphine also induced 
“naïve” morphine tolerance (F(2,21)=5.949; p= 0.0090; Figure 3.5C). Indeed, the D50 for animals 
pretreated with 5 µg of (+)-morphine (D50 = 8.218 mg/kg, CI = 7.144 – 9.293) did not differ from 
animals that received 3 days of (-)-morphine (sc) (D50 = 10.86 mg/kg, CI = 7.461 – 14.26; 
p=0.0513). Additionally, both (-)- and (+)-morphine groups had a significant increase in D50 
(p=0.0072 and p=0.0037, respectively) as compared with saline controls (D50 = 5.921 mg/kg, CI 
= 5.014 – 6.828). Together, these results are the first to indicate that morphine activation of 
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vlPAG glia contributes to the development of morphine tolerance, and that vlPAG TLR4 is both 
necessary and sufficient for the development of morphine tolerance. 
Experiment 3: Acute Systemic Antagonism of TLR4 Potentiated Acute Morphine 
Antihyperalgesia in a Model of Persistent Inflammatory Pain 
Experiment 3.1: (+)-naloxone significantly increased acute morphine antihyperalgesia 
The results from the studies above indicate that antagonism of TLR4 attenuates the development 
of tolerance to morphine, providing additional evidence that glia actively oppose the 
antinociceptive actions of morphine. Therefore, in our final series of experiments we tested if 
blockade of TLR4 potentiated the analgesic effects of acute morphine. As morphine is primarily 
consumed for the alleviation of severe pain, these studies were conducted in animals 
experiencing persistent inflammatory hyperalgesia. Systemic antagonism of TLR4 with (+)-
naloxone (8 mg/kg) significantly potentiated acute morphine antihyperalgesia as compared with 
sc vehicle/sc morphine treated animals (t (11) = 3.811; p = 0.0014; Figure 3.6). Indeed, the 
potency of morphine was significantly increased in animals treated with (+)-naloxone (D50 = 
3.415 mg/kg, CI = 3.093 – 3.737) as compared with vehicle controls (D50 = 5.609 mg/kg, CI = 
4.727 – 6.490). Consistent with previous results, (+)-naloxone, in the absence of morphine, 
exhibited acute antihyperalgesic effects resulting in a slight increase in PWL across the testing 
period 181. These results, together with our previous studies, indicate that TLR4 opposes both the 
acute and chronic effects of morphine.  
Discussion 
The present set of experiments tested the hypothesis that vlPAG glia contribute to the 
development of morphine tolerance through the innate immune receptor toll-like receptor 4 
(TLR4). Here we report that (1) vlPAG microinjections of the general glial metabolic inhibitor 
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propentofylline or the astrocyte inhibitor fluorocitrate significantly decreased morphine-induced 
glia activation in the vlPAG, and attenuated the development of tolerance to systemically-
administered morphine; (2) vlPAG TLR4 antagonism prevented the development of tolerance to 
systemic morphine; and (3) vlPAG TLR4 agonism induced a ‘naïve’ tolerance to subsequent 
challenge doses of morphine. Based on these findings we hypothesized that blockade of TLR4 
would potentiate the antinociceptive effects of morphine in a model of persistent inflammatory 
pain. Indeed, systemic antagonism of TLR4 significantly enhanced the acute antihyperalgesic 
effects of systemic morphine. Together, these data demonstrate a role for vlPAG glia in the 
development of morphine tolerance, establish the vlPAG as a CNS locus through which TLR4 
mediates morphine tolerance development. The results of our acute studies implicate TLR4 as a 
potential therapeutic target for the treatment of pain.  
vlPAG glia contribute to morphine tolerance  
It is now well established that opioids, including morphine, activate spinal glia to produce 
a potent proinflammatory response that opposes both acute and chronic morphine analgesia 73. 
Morphine administration increases the expression of microglia and astrocyte activity markers 
OX-42 and GFAP and induces the release of glially derived proinflammatory cytokines 72,86.  In 
agreement with our previous findings, here we show that in the absence of pain, tolerance to 
morphine developed rapidly 45,173. Indeed, administration of one ED50 dose of morphine (5 
mg/kg) for three days was sufficient to induce behaviorally defined tolerance. Paralleling the 
development of tolerance, OX-42 and GFAP protein levels increased significantly within the 
vlPAG, suggesting the activation of microglia and astrocytes, respectively 173. These results 
demonstrate that the vlPAG proinflammatory response contributes to the development of 
morphine tolerance. Indeed, intra-PAG administration of propentofylline, which inhibits both 
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microglia and astrocyte activity by reducing proinflammatory cytokine release, dose-dependently 
decreased vlPAG microglia and astrocyte activity, and attenuated tolerance to morphine 93,94. 
Decreased astrocyte activity appears to drive this effect in part, as inhibition of astrocytes alone 
with fluorocitrate led to an attenuation of tolerance. Proinflammatory cytokines, particularly 
tumor necrosis factor alpha (TNFa), increase the density and conductance of neuronal GluR2-
lacking AMPA receptors (via neuronal PI3K and TNFR1 but not TNFR2), and decrease GABAA 
receptors via endocytosis. These changes increase mEPSCs and decrease mIPSCs in 
hippocampal slices and cultured hippocampal neurons 145. The proinflammatory cytokine IL-1b 
significantly increases neuronal GluR2-lacking AMPA receptors, albeit to a lesser extent 144,145. 
TNFa also decreases astrocytic glutamate transporter proteins (GLT-1, GLAST) in the spinal 
cord presumably leaving more glutamate available in the synapse 97. Together, these cytokine-
induced changes, among others, effectively increase neuronal excitability 147,148. This increased 
excitation may contribute to morphine tolerance by opposing the inhibitory properties of 
morphine.  
Our findings within the PAG complement a vast literature indicating that spinal cord glia 
contribute to morphine tolerance development, and indicate a role for supraspinal glial cell 
activity as well 72,74,84,92. Consistent with our results, intrathecal administration of propentofylline 
increases acute opioid analgesia and attenuates morphine tolerance 87,93. However, in contrast to 
the spinal cord, where either inhibition of microglia or astrocytes alone is sufficient to attenuate 
the development of morphine tolerance, here inhibition of astrocytes alone was effective in 
attenuating tolerance 72,96. While microglia are classically viewed as initiators of 
neuroinflammation, chronic morphine can cause neurons to release factors that activate both 
microglia and astrocytes (e.g., fractalkine, dynorphin, and nitric oxide), and astrocytes can 
58 
express TLR4 84,85,99,187. Therefore, it is conceivable that while morphine activates both microglia 
and astrocytes, blocking astrocyte activation alone reduces opiate-induced changes in neuronal 
excitability that contribute to morphine tolerance development and maintenance.   
vlPAG TLR4 modulates morphine tolerance development  
There is extensive literature supporting a critical role for glial cell activation in the 
development of morphine tolerance. Until relatively recently, however, the mechanism by which 
opioids induce the activation of glia was unknown. Demonstration that opioid hyperalgesia is 
still observed in neuronal opioid receptor (m, d, and k) knockout mice led to the consideration 
that the anti-analgesic effects of morphine (e.g., tolerance) may be mediated by non-neuronal 
opioid receptors 98. Interestingly, glial activation induced by other stimuli such as neuropathic 
pain or lipopolysaccharide (LPS) administration, also reduces the analgesic efficacy of 
intrathecal morphine, an effect attenuated by intrathecal administration of the neuronal opioid 
receptor inactive antagonist (+)-naloxone 188.  
It is now clear that TLR4 activity opposes morphine analgesia. Hutchinson et al. provided 
convincing in vitro, in vivo, and in silico data indicating that TLR4, along with its co-receptor 
MD-2, binds opioid agonists and antagonists (e.g., morphine and naloxone) in a 
nonstereoselective fashion with both the (-)- and (+)-stereoisomers affecting the TLR4 signaling 
cascade in a manner that maintains their agonistic and antagonistic properties 78.  
Functionally, animals that receive TLR4 antagonism, as well as TLR4 knockout mice, 
exhibit increased responsiveness to the analgesic properties of acute morphine administration 89. 
In addition, systemic (+)-naloxone prevents the development of tolerance to systemic (-)-
morphine 78. Here we establish the vlPAG as a key CNS locus through which TLR4 signaling 
mediates morphine tolerance. Importantly we show dense, and homogeneous expression of MD-
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2 across the rostro-caudal extent of the vlPAG, and report that MD-2 immunoreactivity is 
significantly greater in the vlPAG as compared to the dlPAG, a subregion of the PAG not 
implicated in morphine tolerance development 51. Further, vlPAG microinfusions of the TLR4 
competitive antagonist LPS-RS dose-dependently eliminated the development of morphine 
tolerance to sc morphine. Here, we further demonstrate that intra-vlPAG administration of the 
opioid receptor inactive form of naloxone, (+)-naloxone, which blocks TLR4 signaling in vitro, 
completely abolished the development of tolerance to systemic morphine 78. These results 
suggest that vlPAG TLR4 is necessary for the development of morphine tolerance. Lastly, we 
show that vlPAG microinfusions of several TLR4 agonists induced a ‘naïve’ tolerance to 
subsequent challenge doses of morphine. vlPAG infusions of the prototypical TLR4 agonist LPS, 
the synthetic TLR4 agonist KDO2, and the opioid receptor inactive form of morphine, (+)-
morphine, in the absence of systemic (-)-morphine, all resulted in a tolerance to subsequent doses 
of (-)-morphine, indicating that activation of vlPAG TLR4 is sufficient to induce tolerance.  
TLR4 opposes acute antihyperalgesia 
Our results demonstrating that acute inhibition of TLR4 potentiated morphine analgesia 
in a model of persistent pain have exciting implications for the clinical treatment of chronic pain. 
This work complements previous work demonstrating that TLR4 agonism enhances pain, and 
that TLR4 antagonism potentiates the analgesic efficacy of morphine in the absence of pain 78,80. 
Further, our results support the finding that the opioid receptor inactive, (+)-stereoisomer of 
naloxone attenuates pain in the absence of morphine 181,189. (+)-naloxone has been demonstrated 
to be blood-brain barrier permeable with pharmacokinetic properties similar to its widely 
prescribed stereoisomer (-)-naloxone, indicating that (+)-naloxone could readily translate to 
clinical applications 89,181. Although morphine is amongst the most effective analgesics available, 
60 
chronic morphine treatment leads to a myriad of negative side effects including tolerance. 
Morphine tolerance is particularly problematic as it is often addressed by increasing the dose of 
morphine prescribed. Dose escalation leads to increased risk of developing additional negative 
side effects, including anti-analgesia, addiction, withdrawal, and respiratory depression, and is 
not always sufficient to overcome tolerance and reinstate analgesic efficacy 3,4. Interestingly, the 
proinflammatory glial response to opioids has been implicated in many of the negative side 
effects associated with opioid treatment (e.g., withdrawal, reward, dependence, respiratory 
depression, and tolerance 89,107). As over 90% of chronic pain sufferers are treated with opioids, 
including morphine, these data have exciting implications for pain management 4,85. Indeed, 
decreasing the dose of morphine prescribed by co-administration of (+)-naloxone could enhance 
morphine analgesia and prevent negative consequences of opioid therapy including tolerance 
development. 
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Chapter 3 Figures 
 
Figure 3.1 Summary of morphine tolerance following vlPAG glial metabolic 
inhibition.  
PWL represented as mean D50 + 95% confidence intervals (CI) as a function of cumulative 
injections of morphine in rats treated with (A) vlPAG vehicle + sc Saline ( , n=6), vlPAG 
vehicle + sc Morphine ( , n=9), and vlPAG propentofylline (10fmol , n=5, 100fmol , n=9) 
and sc Morphine, (B) vlPAG vehicle + sc Saline ( , n=6), vlPAG vehicle + sc Morphine ( , 
n=8), and vlPAG minocycline (10fmol , n=9; 1pmol , n=12; or 10pmol , n=4) and sc 
Morphine, and (C) vlPAG vehicle + sc Saline ( , n=6), vlPAG vehicle + sc Morphine ( , n=9), 
and vlPAG fluorocitrate (1fmol , n=5; 10pmol , n=6) and sc Morphine. 
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Figure 3.2 Summary of glial inhibition following vlPAG metabolic glial ihibitors. 
Densitometry of OX-42 (A) and GFAP (B) immunoreactivity in the vlPAG in vlPAG Saline + sc 
Saline (n=6), vlPAG Saline + sc Morphine (n=8), vlPAG propentofylline (10 fmol, n=5 and 100 
fmol, n= 9) + sc Morphine, vlPAG minocycline (10 fmol, n=9; 1 pmol, n= 12; and 10 pmol, n=4) 
+ sc Morphine, and vlPAG fluorocitrate (1 fmol, n=5 and 10 pmol, n=6) + sc Morphine groups. 
*p < 0.05, +p < 0.01, and #p < 0.001 indicate that groups are significantly different from the 
vlPAG Saline + sc Morphine group. Insets are representative photomicrographs (10X) of OX-42 
(A) and GFAP (B) immunoreactivity in the vlPAG (Bregma -7.08) of animals treated with 
vlPAG Saline + sc Saline, vlPAG Saline + sc Morphine, vlPAG 10fmol PPF + sc Morphine, and 
vlPAG 10pmol Mino + sc Morphine (from left to right; A) and vlPAG Saline + sc Saline, vlPAG 
Saline + sc Morphine, vlPAG 10fmol PPF + sc Morphine, and vlPAG 10pmol FC + sc Morphine 
(from left to right; B). 
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Figure 3.3 Summary of MD-2 in the dorsal and ventrolateral PAG. 
Myeloid differentiation factor-2 (MD-2) immunoreactivity in the vlPAG and dlPAG of normal 
adult male rats (n=5) collapsed across Bregma levels (A) and separated by Bregma level (B) 
represented as mean + SEM. Note that dlPAG is not present at Bregma -8.28 and -8.76 130. 
Representative photomicrographs of dlPAG and vlPAG MD-2 immunoreactivity shown at 4X 
(middle) and 10X (right) magnifications (A, inset). Aq denotes the location of the cerebral 
aqueduct. 
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Figure 3.4 Summary of morphine tolerance following TLR4 antagonism. 
PWL represented as mean D50 + 95% confidence intervals (CI) as a function of cumulative 
injections of morphine in rats treated with (A) vlPAG Vehicle + sc Saline ( , n=8), vlPAG 
Vehicle + sc Morphine ( , n=7), and vlPAG LPS-RS (1.7 mg , n=5; 2.4 mg , n=6) + sc 
Morphine, and (B) vlPAG Vehicle + sc Saline ( , n=8), vlPAG Vehicle + sc Morphine ( , n=7), 
and vlPAG (+)-Naloxone (5 mg/0.5 ml) + sc Morphine ( , n=6), and vlPAG (+)-Naloxone + sc 
Vehicle ( , n=4). 
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Figure 3.5 Summary of morphine tolerance following TLR4 agonism. 
PWL represented as mean D50 + 95% confidence intervals (CI) as a function of cumulative 
injections of morphine in rats treated with (A) vlPAG Vehicle ( , n=8), vlPAG Vehicle + sc 
Morphine ( , n=7), and vlPAG LPS (1.7 mg , n=7 or 5 mg , n=6) (B) vlPAG Vehicle ( , 
n=10), vlPAG Vehicle + sc Morphine ( , n=7), and vlPAG KDO2  (0.5 mg , n=5; 1 mg , 
n=3; or 5 mg , n=6) and (C) vlPAG Vehicle ( , n=7), vlPAG Vehicle + sc Morphine ( , n=7), 
and vlPAG (+)-morphine  (5 mg , n=10).  
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Figure 3.6 Summary of acute morphine antihyperalgesia following acute (+)-
naloxone. 
PWL represented as mean D50 + 95% confidence intervals (CI) across time (minutes) in rats 
treated with one injection of sc (+)-naloxone (8 mg/kg) and cumulative injections of sc morphine 
( , n=5), one injection of sc vehicle (1ml/kg) and cumulative injections of sc morphine ( , n=8), 
and one injection of sc (+)-naloxone (8 mg/kg) and repeated injections of sc vehicle ( , n=3). All 
injections were subcutaneous. (+)-naloxone (or vehicle control) was injected immediately after 
baseline testing (Time 0). Twenty-four hours before PWL testing all animals received an 
injection of CFA into the hindpaw (200 µl). 
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 Abstract 
Opioid-based narcotics remain an integral part of clinical pain management with 
morphine being one of the most effective drugs. However, the acute and long-term analgesic 
efficacy of morphine is limited by the ensuing neuroinflammatory response. The midbrain 
periaqueductal gray (PAG) is an essential neural substrate for opioid-mediated analgesia, and we 
have previously reported that chronic morphine administration activates ventrolateral PAG 
(vlPAG) glia via the innate immune receptor toll-like receptor 4 (TLR4), leading to the 
development of behaviorally-defined tolerance. TLR4 activation results in a robust release of 
cytokines, including tumor necrosis factor a (TNF), and TNF signaling can increase the 
excitability of neurons by modulating glutamate homeostasis and signaling via neuronal TNF 
receptor 1 (TNFR1). Our overarching hypothesis is that TNF-induced increases in neural 
excitability oppose the hyperpolarizing effects of morphine, resulting in opioid tolerance. Using 
a lentiviral vector encoding dominant negative TNF (DN-TNF), here we demonstrate that intra-
PAG sequestration of soluble TNF (solTNF) abolished tolerance to systemic morphine as well as 
naïve tolerance to morphine induced by intra-vlPAG injections of the TLR4 agonist LPS. 
Additionally we demonstrate the efficacy of the novel, BBB permeable DN-TNF peptide 
XPro®1595 in preserving morphine efficacy following chronic morphine exposure. Tolerance 
was accompanied by a significant increase in vlPAG TLR4 and proinflammatory cytokine (IL-
1β) mRNA and decrease in vlPAG astrocytic glutamate transporter protein mRNA (GLT-1 and 
GLAST) that was attenuated or eliminated by sequestration of solTNF. These results support our 
working hypothesis and indicate that morphine binds to TLR4 within the vlPAG, leading to the 
release of solTNF. Our results further suggest that solTNF mediates morphine tolerance in the 
PAG via neuronal TNFR1 signaling and augmentation of glutamate homeostasis.  
69 
Introduction 
Opioid therapy remains the most common and effective strategy for severe and chronic 
pain management3. However decreased analgesic efficacy over time (i.e., tolerance) significantly 
impedes treatment for approximately 60% of the patient population8. It is now clear that opioids, 
including morphine72-81, elicit a robust neuroinflammatory response that enhances nociceptive 
transmission71 and contributes to opioid tolerance72-75,82-87. The proinflammatory effects of 
morphine are not mediated via signaling at classical opioid receptors, but rather, through the 
innate immune receptor TLR481. Opioids bind to myeloid differentiation factor-2 (MD-2), a 
glycoprotein that binds to both LPS and the extracellular domain of TLR478,79.  Opioid binding to 
the TLR4/MD-2 complex results in the activation of MAP kinases and NF-kB, leading to the 
robust release of proinflammatory cytokines, including TNF, IL-1β, and IL-678,79,81.  
A nearly ubiquitous characteristic of opioid-induced neuroinflammation is TNF 
production. Chronic systemic or intrathecal morphine administration increases TNF 
mRNA84,86,102,103 and protein53,86,101,102,104,105 in the rodent spinal cord, and proinflammatory 
cytokine levels increase with the chronicity of morphine treatment84. Inhibition of spinal TNF 
signaling decreases morphine-induced release of proinflammatory cytokines and attenuates p38 
MAPK activation 54,102,106. Functionally, immunomodulatory drugs that attenuate, abolish, or 
even reverse morphine tolerance (e.g., ibudilast (AV411)97,107, minocycline76,91,96,97,108, 
fluorocitrate72,82, propentofylline82,87,93,94,109) decrease the expression of TNF. However, these 
immunomodulatory drugs have widespread and non-specific effects, altering expression levels of 
several cytokines also implicated in opioid tolerance, including IL-1β86,101,110 and IL-686,87,101. 
While these data indicate that spinal TNF plays a significant role in morphine-induced 
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inflammation and the development of morphine tolerance72-74,76,84-87,93,111,112, remarkably few 
studies have directly tested the role of TNF in isolation54,102,106.  
TNF naturally exists in two forms; the more common form, transmembrane TNF 
(tmTNF), is cleaved by the TNF converting enzyme TACE to release the less abundant form, 
soluble TNF (solTNF)190. solTNF binds exclusively to TNF receptor I (TNFRI), which signals 
via the proinflammatory pathways p38 MAPK and NFkB112,191. In contrast, tmTNF binds to 
either TNFRI or TNFRII, and is a critical factor for innate immunity to infection192. 
To date, anti-TNF biologics used to test the role of TNF in opioid tolerance attenuate the 
actions of both forms of TNF. For example, viral expression106 or chronic infusion54,102 of decoy 
TNF receptors in the spinal cord, which alter the action of both solTNF and tmTNF, attenuates 
morphine tolerance. Currently there are FDA-approved non-selective biological inhibitors that 
sequester both forms of TNF, but these drugs have been associated with neurological deficits and 
demyelinating disease in patients who were previously neurologically normal193,194.  
TNF significantly increases neuronal excitability, in part, through TNFRI signaling. For 
example, morphine-induced TNF signaling decreases expression of the astrocytic glutamate 
transporter GLT-1 and glutamate/aspartate transporter GLAST54, and increases the expression of 
AMPA and NMDA receptor subunits in the spinal cord54. In hippocampal slices, TNF signaling 
through TNFRI (solTNF and tmTNF) increases neuronal GluR2-lacking AMPA receptor 
expression and conductance, and decreases neuronal GABAA receptor expression145. As 
morphine exerts its analgesic effects by hyperpolarizing neurons28,31,42,64, TNF-mediated 
alterations in neuroexcitability may provide an underlying mechanism driving the development 
of opioid tolerance62,63,195-204. 
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Previous studies examining the impact of glia signaling on morphine tolerance were 
focused on the spinal cord dorsal horn. However, the midbrain ventrolateral periaqueductal gray 
(vlPAG) has been shown repeatedly to be a more critical site for morphine action24,45,175,205,206. 
Repeated administration of morphine into the vlPAG results in the rapid development of 
tolerance49,50, while intra-vlPAG administration of the opioid antagonist naltrexone significantly 
attenuates tolerance to systemic morphine24. Opioid tolerance is mediated, in part, via vlPAG 
TLR4 signaling 82,83. Administration of the TLR4 agonist LPS directly into the PAG induces a 
‘naïve’ tolerance to morphine, while intra-PAG administration of the TLR4 antagonists LPS-RS 
or (+)-naloxone abolishes morphine tolerance82. As morphine-induced TLR4 signaling results in 
robust TNF release81, the present studies tested the hypothesis that morphine tolerance is due to 
altered vlPAG astrocytic glutamate homeostasis and increased neuronal excitability that is 
mediated by TLR4 solTNF signaling.  
Materials and Methods 
Subjects 
Pathogen free male Sprague Dawley rats (250-350g; Charles River; Wilmington, MA) 
were pair-housed on a 12:12 hour light:dark cycle (lights on at 7:00 am). Access to food and 
water was available ad libitum except during behavioral testing. The Institutional Animal Care 
and Use Committee (IACUC) at Georgia State University approved all studies. All efforts were 
made to reduce the number of animals used and to minimize any possible suffering by the 
animal.  
Cloning and preparation of lentiviral stocks 
The inhibitor protein dominant-negative TNF (DN-TNF) is a well-characterized variant 
of native human TNF that has been engineered to rapidly form heterotrimers with native soluble 
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TNF (solTNF) in rat and mouse brain. DN-TNF heterotrimerization with native solTNF 
effectively sequesters native solTNF and precludes it from initiating signaling through TNFRI by 
preventing receptor binding207, while sparing the beneficial effects mediated by the 
transmembrane TNF (tmTNF) signal192,207. The human full-length DN-TNF DNA sequence 
(TNF variant with two point mutations; A145R/I97T207) and the enhanced green fluorescent 
protein DNA sequence (GFP; reporter) were subcloned into a constitutive self-inactivating 
lentiviral vector under the chicken b-actin cytomegalovirus (CAG) promoter. Both DN-TNF-
GFP and GFP (control virus) lentiviral stocks were produced and purified at Emory University’s 
Viral Vector Core according to previously published protocols208. The final titers were 1 x 77 
IU/ml for lenti-DN-TNF-GFP and 2 x 108 IU/ml for lenti-GFP control. The feasibility and 
efficacy of the virus have been well demonstrated in vitro and in vivo208-210 
Lentivirus infection and morphine treatment 
Animals in Experiment 1.1 received bilateral intra-vlPAG (AP:  1.7 mm, ML: + 0.6 mm, 
DV: -5.5 mm from lambda) microinfusions (2.5 µl/ 4 minutes/ side)207 of a lentiviral vector 
encoding DN-TNF and GFP (lenti-DN-TNF) or encoding GFP only (lenti-GFP) using a 
Hamilton syringe (5 µl) attached to a stereotaxic arm. The syringe was left in place for 60 
seconds following each infusion to prevent backflow upon removal. All animals were 
anesthetized to a deep surgical plane with 5% Isoflurane (Baxter Healthcare Corporation; 
Deerfield, IL) and maintained at 2-5% Isoflurane throughout microinfusions. Skin staples were 
used to close the skin, and animals were given topical triple antibiotic ointment (Bacitracin, 
Neomycin, Polymyxin) to prevent infection and topical lidocaine hydrochloride (2%; Akorn, 
Inc.) to ameliorate pain. One week following virus infusions, animals were administered 
morphine (5 mg/kg, sc; National Institute on Drug Abuse (NIDA), Bethesda, MD) or vehicle 
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(sterile saline; 1 ml/kg; sc) once a day for 3 consecutive days, resulting in four treatment groups: 
lenti-DN-TNF + Morphine (n = 10), lenti-DN-TNF + Saline (n = 5), lenti-GFP + Morphine (n = 
10), and lenti-GFP + Saline (n = 4). Animals were removed from the lenti-DN-TNF + Saline 
group (n=5) and from the lenti-GFP + Saline group (n = 6) because cannulae were located 
outside of the PAG, or they did not show robust GFP expression in the vlPAG. The 5 mg/kg dose 
was chosen based on our previous studies demonstrating this to be the 50% effective dose (ED50) 
for systemic morphine in male rats122,125.  
Ventrolateral periaqueductal gray cannulation, lentivirus infection, and LPS microinfusions  
In Experiment 1.2 animals were bilaterally cannulated and infused with lenti-DN-TNF or 
lenti-GFP with a Hamilton syringe (5 µl) inserted through guide cannulae. Animals were 
implanted with bilateral guide cannulae (22 gauge; Plastics One; Roanoke, VA) aimed at the 
ventrolateral PAG (AP:  1.7 mm, ML: + 0.6 mm, DV: -5.0 mm from lambda) using stereotaxic 
techniques as previously described82,114. Animals recovered for 1 week before lentivirus 
infection. Using a Hamilton syringe (5 µl) inserted through implanted guide cannulae (-5.5 mm 
DV), animals received bilateral intra-vlPAG microinfusions (2.5 µl/ 4 minutes/ side)207 of lenti-
DN-TNF-GFP or lenti-GFP as described above. To test a direct role for TLR4-mediated TNF 
release in morphine tolerance development, animals in Experiment 1.2 received bilateral intra-
vlPAG infusions of the TLR4 agonist lipopolysaccharide (LPS; 5 µg/ 0.5µl/ side/ 2 minutes; 
Sigma) once a day for three consecutive days to induce a naïve tolerance to morphine as 
previously described82. LPS is the prototypical TLR4 agonist and has been shown to 
competitively bind to TLR4, resulting in the production of TNF. LPS doses and injection time-
course were chosen based on our previous studies demonstrating that this dosing is sufficient to 
induce naïve tolerance to morphine82. Control animals received vehicle (sterile saline; 0.5µl/ 
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side/ 2 minutes) once a day for three consecutive days resulting in the following experimental 
groups: lenti-DN-TNF + PAG LPS (n = 9), lenti-DN-TNF + PAG Saline (n = 6), lenti-GFP + 
PAG LPS (n = 4), and lenti-GFP + PAG Saline (n = 6). Animals were removed from the lenti-
DN-TNF + PAG LPS (n=1), lenti-DN-TNF + PAG Saline group (n=4), lenti-GFP + PAG LPS (n 
= 6), and from the lenti-GFP + PAG Saline group (n = 4) because cannulae were located outside 
of the PAG, or they did not show robust GFP expression in the vlPAG.    
XPro®1595 and morphine treatment 
XPro®1595 is a novel, brain-permeant, dominant negative TNF variant with FDA IND 
status that selectively diminishes the inflammatory signal of soluble TNF (> 2500-fold)192,207 in 
the same manner as the virally expressed DN-TNF in Experiment 1211. A preemptive dose of 
XPro®1595 (10 mg/kg; sc) was administered 1 day before the first morphine (5mg/kg; sc) 
injection to allow DN-TNF adequate time to reach the brain. A booster injection of XPro®1595 
was administered with the 3rd morphine injection to maintain DN-TNF levels in the brain (half 
life = 18 hours; personal communication from Dr. Malu Tansey). Control animals received 
equivolume saline, resulting in the following experimental groups: XPro + Morphine (n = 11), 
XPro + Saline (n = 8), Vehicle + Morphine (n = 11), and Vehicle + Saline (n = 8).  
Nociceptive testing 
Nociception was assessed using the paw thermal stimulator126. Briefly, for this test, the 
rat is placed in a clear Plexiglas box resting on an elevated glass plate maintained at 30o C. A 
radiant beam of light is positioned under the plantar surface of the hindpaw and the time for the 
rat to remove the paw from the thermal stimulus is electronically recorded as the paw withdrawal 
latency (PWL). A maximal PWL of 20.48 seconds was used to prevent excess tissue damage due 
to repeated application of the noxious thermal stimulus. Animals were acclimated to 
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experimenter handling (once a day for one week) prior to testing, and acclimated to the testing 
apparatus (30 minutes a day for 3 consecutive days) 3 days before the first sc injection. All 
behavioral testing took place between 12:00 pm and 5:00 pm (lights on at 7:00 am). Groups were 
coded and testing was conducted blind with respect to group assignment. All groups were 
represented in each round of testing and testing order was counterbalanced across testing days. In 
Experiments 1.1 and 2, paw withdrawal latencies (PWL) were determined prior to and 15 
minutes post-injection (morphine or saline; day 1 and day 3) to assess the time course of 
tolerance development.  
Tolerance Assessment 
Morphine tolerance was assessed on day 4 by injecting cumulative doses of morphine 
every 20 min, resulting in doses of 1.8, 3.2, 5.6, 8.0, 10.0, and 18.0 mg/kg (sc) as previously 
described45,173. Day 1 was defined as the first day of morphine pretreatment (Experiments 1.1 & 
2), LPS pretreatment (Experiment 1.2), or vehicle pretreatment. Nociception was assessed using 
the paw thermal stimulator 15 min after each injection122,126 as described above.  
Behavioral data analysis and presentation  
Paw withdrawal latencies (PWL; seconds) were measured in triplicate and averaged for 
each animal. Half-maximal effective dose (ED50) and 95% confidence intervals (CI) were 
calculated from dose-response curves generated using GraphPad/Prism software82. Changes in 
ED50 between groups were assessed using ANOVA, and Fisher’s post hoc tests were used to 
determine specific group differences when a significant main effect was observed 
(GraphPad/Prism). All values are reported as Mean ED50 + 95% CI; p < 0.050 was considered 
significant.  
Determination of lentivirus expression 
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Immediately following tolerance assessment, all animals from Experiment 1 were 
decapitated, and brains removed, flash frozen in 2-methylbutane on dry ice, and stored at -80°C 
until processing. All tissue processing was conducted using RNase free technique, and working 
surfaces and slide boxes were treated with RNase Away (Thermo Fisher Scientific). Brains were 
sectioned into 25 µm coronal sections, immediately slide mounted, and stored in slide boxes with 
desiccant at -80°C. A 1:6 series through the rostrocaudal axis of the PAG (Bregma -7.04 to -
8.30) was used to verify virus infection by visualizing GFP using a Nikon microscope (10 X 
magnification) with a fluorescent (FITC) filter. Animals with GFP spread located outside of the 
PAG were excluded from all analyses.  
GLT-1, GLAST, and EAAC1 in situ hybridization 
In a subset of animals (n= 4-6/group), a separate 1:6 series through the caudal axis of the 
PAG (Bregma -7.04 to -8.30) was used for in situ hybridization.  DNA fragments of GLAST, 
GLT-1 and, to determine which cell type (glia or neuron) is responsible for alterations in 
glutamate homeostasis, we examined the neuronal excitatory amino acid carrier 1 (EAAC1). 
DNA fragments were amplified from rat brain cDNA using polymerase chain reaction (PCR). 
PCR products (1371-bp, 1363-bp, and 1411-bp for GLAST, GLT-1, and EAAC1, respectively) 
were inserted into pCRII vector (Invitrogen, CA) and were sequenced to verify identification of 
each gene (Genbank accession number, NM_019225, NM_017215, and NM_013032, 
respectively). Sense and antisense 35S-UTP-labelled RNA probes for GLAST, GLT-1, and 
EAAC1 mRNA were generated using in vitro transcription with the linearized plasmids and T7 
or SP6 RNA polymerases (Promega, WI). Brain sections were hybridized with the probes and 
washed as previously described212. The sections were then exposed to Kodak BioMax MR films 
for 4 weeks. 
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In situ hybridization densitometry 
14C microscales (GE Healthcare Life Sciences, USA) were used to create standard curves 
(R2 > 0.97) for each assay. Scion Image software (NIH and Scion Corp., USA) and a MTI CCD 
72 camera and Northern Light box (Imaging Research, Inc., CN) were used to capture 12-bit 
grayscale images of each section. Optical densities in an area of 0.8 X 1.0 mm were measured in 
the vlPAG and inferior colliculus (IC). The mean pixel value from 3 sections of each brain per 
region was recorded and measures corrected for nonspecific binding by subtracting background 
adjacent to the ROI that lacked hybridization. Changes in mRNA between groups were assessed 
using ANOVA, and Fisher’s post hoc tests were used to determine specific group differences 
when a significant main effect was observed (SPSS). Mean specific hybridization is reported as 
the disintegrations per minute per milligram of tissue (dpm/mg) + SEM; p < 0.050 was 
considered significant.  
Immunoassay determination of XPro®1595 levels 
Cerebrospinal fluid (CSF), plasma, and brains were collected from animals pretreated 
with XPro + Morphine (n=6), XPro + Saline (n=3), Vehicle + Morphine (n = 6), and Vehicle + 
Saline (n = 3; Experiment 2) for measurement of XPro®1595 concentrations. Animals were 
removed from the XPro + Saline group (n=3) and from the Vehicle + Saline group (n = 3) 
because of damage to the tissue. Immediately prior to decapitation, animals were anesthetized 
with BeuthanasiaD (160 mg/kg; i.p.) and cerebrospinal fluid (CSF) was collected via the cisterna 
magna puncture method213 with minor modifications. Rats were positioned with the nose pointed 
downward at a ~45° angle and the cisterna magna was exposed by dissecting through the 
musculature overlying the posterior atlantooccipital membrane. The membrane was punctured 
with a glass pipette tip, and was collected via capillary action, and CSF was stored at -80°C. Rats 
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were then decapitated as described above, and trunk blood was collected in EDTA coated tubes, 
gently mixed, and put on ice for 1-2 hours. Tubes were centrifuged at 2000 rmp for 18 minutes at 
4°C and the plasma was isolated and stored at -80°C. Immediately after trunk blood collection, 
brains were removed and flash frozen as described above. All tissue collection was complete 
within 2 minutes. Midbrain, CSF and plasma (diluted 1:4) levels of XPro®1595 were measured 
using the Meso Scale Discovery anti-human TNF ultrasensitive electrochemiluninescent 
detection immunoassay (cat # K151BHC-1) and quantified using the Meso Scale Discovery 
SECTOR Imager 2400-A (Meso Scale Diagnostics, LLC, Rockville, MD). To increase assay 
sensitivity for determination of levels211, XPro®1595 protein was used instead of the supplied 
human TNF protein for generation of standards. Data were analyzed using the Meso Scale 
Discovery integrated data analysis software, which converts signals to pg/ml values.  The 
remaining tissue lysates were assayed for total protein using a Pierce BCA protein assay kit 
(Thermo Scientific) to ensure equivalent protein loading across samples, and measured on a 
Spectramax plate reader at 562 nm using SoftMax v5.2 software (Molecular Devices, CA). Data 
are presented as ng/ml. All samples were assayed in duplicate by an experimenter blinded to 
treatment history. 
vlPAG cytokine and TLR4 qPCR  
Brains were collected from animals (n = 5 per group) treated with XPro + Morphine, 
XPro + Saline, Vehicle + Morphine, and Vehicle + Saline, blocked (Bregma -6.96 to -
8.52)130,173, and flash frozen as described above. One-millimeter bilateral micropunches were 
taken through the vlPAG, and stored in RNAse, DNase, and pyrogen free tubes (1.5ml Fisher 
Scientific) until RNA isolation for quantitative RT-PCR of proinflammatory cytokines and TLR4 
mRNA. Assays were conducted using RNase free technique. Total RNA was isolated from 
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vlPAG tissue punches using a standard TRIzol Reagent method (Invitrogen Life Technologies, 
Carlsbad, CA); concentration and purity was assayed on a nanospec, and all RNA was diluted to 
60 ng/ml with nanopure water, and converted to cDNA using the Cloned AMV First-Strand 
cDNA Synthesis Kit (Life Technologies). cDNA sequences were found using GenBank at the 
National Center for Biotechnology Information (NCBI; www.ncbi.nlm.nih.gov). Measurement 
of gene expression included the following: Tlr4, Tnf, Il6, Il1b, , Il10, and the housekeeping gene 
Gapdh. Primer sequences were taken from previously published sources (TLR4214, IL-10215, and 
IL-6165) or designed (TNF, IL-1β, GAPDH) using PrimerQuest (Integrated DNA Technologies, 
Inc. (IDT), Coralville, IA), and tested for sequence specificity using the Basic Local Alignment 
Search Tool (BLAST) at NCBI (Tlr4; NM_019178, Tnf; NM_012675), Il6; NM_012589, Il1b;  
NM_031512, Il10; NM_012854, and Gapdh; NM_017008). All primers were obtained from 
IDT. Amplification products from step down PCR (60 °C – 50°C) were run on a 2% agarose gel 
with 0.002% ethidium bromide at 5V per cm for 60 minutes with a DNA ladder (GeneRuler, 
Thermo Scientific) to verify gel position and lack of doublets as a first pass analysis of primer 
specificity (Figure 6f). Bands were isolated under UV light, and DNA was extracted using the 
QIAquick Gel Extraction Kit (Qiagen; Venlow, Limburg). Amplification products of forward 
and reverse primers were sequenced by the GSU Biology Department Core Facility and analyzed 
with 4Peaks software (nucleobytes.com; Netherlands, Amsterdam) and BLAST to verify 
identification of each gene (Tlr4; 96/79% (forward/reverse) query coverage with NM_019178, 
Tnf; 80/43% with NM_012675, Il6; 75/82% with NM_012589, Il1b; 100/91% with NM_031512, 
and Il10; 89/88% with NM_012854). Finally, primer specificity was further tested via melt curve 
analysis to verify one single peak (one amplification product), and serial dilution curve analysis 
to test efficiency, sensitivity, and working range. An acceptable slope (CT value for each dilution 
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against the log of the quantity of cDNA used for each reaction) was between + 0.1 units from the 
control (CYCLOB, slope -3.2 to -3.4). Following primer validation, a temperature gradient PCR 
was run to determine the optimal annealing temperature for each primer set (57°C was best for 
all), and primers (forward and reverse) were titrated for optimal concentration pairings (listed in 
Table 4.2). All primers were designed to span exon/exon boundaries and thus exclude 
amplification of genomic DNA. Primer sequences are presented in Table 4.2. PCR amplification 
of cDNA was performed using SYBR Select Master Mix (Invitrogen Life Technologies). 
Formation of PCR product was monitored and quantified in real time using the 7500 Fast Real-
Time PCR System (Life Technologies). Relative gene expression was determined by taking the 
expression ratio of the gene of interest to Gapdh. Data are normalized to the Vehicle + Saline 
condition. Changes in mRNA between groups were assessed using an ANOVA on ranks 
(Kruskal-Wallis), and Mann Whitney U post-hoc comparisons were used to determine specific 
group differences when a significant main effect was observed (SPSS). We used nonparametric 
statistics as our data did not reach the assumptions of normality; Vehicle + Saline controls had 
very high variability which lead to a lack of homogeneity of variance in the data. Data is 
expressed as median; p < 0.050 was considered significant. 
Results 
Sequestration of vlPAG solube TNF eliminated tolerance to systemic morphine  
The inhibitor protein dominant-negative TNF (DN-TNF) is a well-characterized variant 
of native human TNF that has been engineered to rapidly form heterotrimers with native soluble 
TNF (solTNF) in rat and mouse brain. Human DN-TNF and GFP, or GFP alone were expressed 
in the vlPAG via lenti-viral infection (lenti-DN-TNF or lenti-GFP, respectively). DN-TNF 
heterotrimerization with native solTNF effectively sequesters native solTNF and precludes it 
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from initiating signaling through neuronal TNFRI by preventing receptor binding207, while 
sparing the beneficial effects mediated by the transmembrane TNF (tmTNF) signal192,207. All 
animals included in behavior analysis demonstrated robust virus-induced GFP expression (Figure 
1b) in the vlPAG as indicated by FITC microscopy (Figure 4.1b). Baseline and post-injection 
PWLs did not differ between lenti-DN-TNF and lenti-GFP animals treated with systemic saline, 
indicating that virus expression did not alter basal nociceptive thresholds (Figure 4.1c, black 
symbols). Administration of morphine on Day 1 and Day 3 produced an increase in PWL in both 
lenti-DN-TNF treated animals and lenti-GFP controls (red symbols). There was no difference in 
the analgesic potency of morphine between lenti-GFP and lenti-DN-TNF treated animals on Day 
1 (p = 0.837), indicating that virus expression did not alter acute morphine analgesia. ANOVA 
revealed a significant main effect of treatment on Day 3 (F(3,21) = 29.49; p < 0.000), with the 
antinociceptive potency of morphine being significantly lower in animals pretreated with lenti-
GFP as compared with lenti-DN-TNF (p < 0.000). Morphine efficacy did not differ between 
days in animals pretreated with lenti-DN-TNF, indicating maintenance of analgesia (i.e., no 
tolerance). Administration of cumulative doses of morphine on Day 4 produced an increase in 
PWL in all animals tested (Figure 1d). ANOVA revealed a significant main effect of treatment 
(F(3, 195) = 49.64; p <0.0001). Post hoc analysis revealed that pretreatment with lenti-GFP + 
Morphine resulted in a significant threefold rightward shift in the dose-response curve (ED50 = 
7.47 mg/kg) as compared with lenti-GFP + Saline controls (ED50 = 2.50 mg/kg; p = 0.010; Table 
1), indicating tolerance to morphine. Intra-vlPAG pretreatment with lenti-DN-TNF preserved the 
antinociceptive potency of morphine (ED50 = 2.66 mg/kg) compared with animals made tolerant 
to morphine (lenti-DN-TNF + Morphine vs. lenti-GFP + Morphine; p = 0.013). Indeed, these 
animals did not differ from saline controls (lenti-DN-TNF + Morphine vs. lenti-GFP + Saline; p 
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= 0.149). Together, these results indicate that vlPAG solTNF is necessary for the development of 
tolerance to subcutaneous morphine.  
Sequestration of vlPAG solube TNF eliminated morphine tolerance induced by vlPAG LPS 
To test our hypothesis that the effects of solTNF are mediated by TLR4 signaling, a 
separate group of animals received pretreatment with lenti-DN-TNF or lenti-GFP and intra-
vlPAG infusions of the TLR4 agonist LPS to induce a naïve tolerance to morphine. All animals 
included in behavior analysis demonstrated robust virus-induced GFP expression in the vlPAG 
as indicated by FITC microscopy (Figure 4.2a). Administration of cumulative doses of morphine 
on Day 4 (first morphine exposure) produced an increase in PWL in all animals tested (Figure 
4.2b). ANOVA indicated a significant main effect of treatment (F(3,167) = 37.31; p < 0.000). 
Replicating our previously published findings82, 3 vlPAG infusions of LPS was sufficient to 
induce ‘naïve’ morphine tolerance, as indicated by a significant rightward shift in the dose 
response curve (lenti-GFP + PAG LPS; ED50 = 6.00 mg/kg) as compared with lenti-GFP + PAG 
Saline controls (ED50 = 2.37 mg/kg; p = 0.015; Table 4.1). Intra-vlPAG pretreatment with lenti-
DN-TNF preserved the antinociceptive potency of morphine (lenti-DN-TNF  + PAG LPS; ED50 
= 3.26 mg/kg) compared with animals made tolerant to morphine by vlPAG LPS (lenti-GFP + 
PAG LPS; p = 0.012). Indeed, lenti-DN-TNF + PAG LPS animals did not differ from lenti-DN-
TNF + PAG Saline controls (p = 0.067). These results support our hypothesis that morphine acts 
through TLR4 to increase solTNF signaling, and decrease morphine efficacy.  
Chronic systemic morphine decreased vlPAG GLT-1 and GLAST mRNA in a solTNF-dependent 
manner 
We next tested the hypothesis that solTNF contributes to tolerance development by 
decreasing GLT-1 and GLAST, the primary source of glutamate reuptake in the brain, and 
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investigated changes in the neuronal glutamate transporter EAAC1. In situ hybridization (ISH), 
in combination with densitometry, was used to measure GLT-1, GLAST, and EAAC1 mRNA in 
the caudal vlPAG (Figure 4.3). ANOVA indicated a significant main effect of treatment on 
vlPAG GLT-1 mRNA (F(3,23) = 3.58; p = 0.029, Figure 4.3a). Post hoc analysis revealed that 
morphine administration for 3 days significantly decreased vlPAG GLT-1 mRNA, as compared 
with saline controls (lenti-GFP + Morphine vs. lenti-GFP + Saline; p = 0.004). Lentiviral 
expression of DN-TNF in the vlPAG rescued the expression of GLT-1 mRNA. Indeed lenti-DN-
TNF + Morphine animals did not differ from lenti-GFP + Saline controls (p = 0.128). Similar to 
what was noted for GLT-1 mRNA, chronic morphine significantly decreased vlPAG GLAST 
mRNA (F(3,26) = 6.681; p = 0.002, Figure 4.3b) as compared with saline controls (lenti-GFP + 
Morphine vs. lenti-GFP + Saline; p < 0.000). vlPAG DN-TNF expression was sufficient to 
prevent the morphine-induced decrease in vlPAG GLAST mRNA, as lenti-DN-TNF + Morphine 
animals did not differ from lenti-GFP + Saline controls (p = 0.494). There were no differences 
noted in vlPAG EAAC1 mRNA expression (F(3,26) = 0.876; p = 0.466), suggesting that morphine 
preferentially alters astrocytic glutamate transport in the vlPAG. Morphine decreased astrocytic 
glutamate transporter mRNA in a site specific manner, as the adjacent inferior colliculus (IC) did 
not differ in GLT-1 or GLAST mRNA (F(3,26) = 1.489; p = 0.241 and F(3,23) = 1.471; p = 0.249, 
respectively). The inferior colliculus was chosen because there is a high expression of MOR in 
this region, but the inferior colliculus is not involved in morphine analgesia6. Interestingly, 
ANOVA indicated a significant effect of treatment on IC EAAC1 mRNA (F(3, 26) = 3.720; p = 
0.024, Figure 4.3c inset), with morphine significantly increasing expression as compared with 
controls (lenti-GFP + Morphine vs. lenti-GFP + Saline; p < 0.000). These results support our 
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hypothesis, and suggest that solTNF contributes to morphine tolerance development by altering 
astrocyte-mediated glutamate homeostasis in the vlPAG.  
Chronic vlPAG TLR4 agonism decreased vlPAG GLT-1 and GLAST mRNA in a solTNF-
dependent manner 
Given that LPS binding to TLR4 is a potent inducer of TNF expression, and that chronic 
vlPAG LPS administration leads to morphine tolerance82, we also hypothesized that GLT-1 and 
GLAST would be decreased in animals made tolerant to morphine by LPS. Similar to what was 
noted for chronic systemic morphine exposure, chronic vlPAG microinfusions of LPS decreased 
vlPAG GLT-1 and GLAST mRNA (F(3,12) = 7.268; p = 0.005, and F(3,10) = 7.321; p = 0.007, 
respectively), and did not alter vlPAG EAAC1 mRNA (F(3,10) = 1.982; p = 0.166; Figure 4.4). 
Lenti-GFP + PAG LPS animals had significant decreases in GLT-1 and GLAST mRNA as 
compared with lenti-GFP + PAG Saline animals (p = 0.005, Figure 4.4a and p = 0.002, Figure 
4.4b, respectively). vlPAG DN-TNF expression rescued GLT-1 mRNA (lenti-DN-TNF + PAG 
LPS vs. lenti-GFP + PAG Saline; p = 0.723), and increased, but did not rescue GLAST mRNA 
(lenti-DN-TNF + PAG LPS vs. lenti-GFP + PAG Saline; p = 0.044). There were no differences 
in IC GLAST or EAAC1 mRNA (F(3,10) = 0.347; p = 0.792, Figure 4.4b inset and F(3,13) = 0.659; 
p = 0.592, Figure 4.4c inset, respectively), however LPS significantly decreased GLT-1 mRNA 
in the IC (F(3,12) = 3.169; p = 0.0064, lenti-GFP + PAG LPS vs. lenti-GFP + PAG Saline, p = 
0.015, Figure 4.4a inset). These results support our hypothesis, and indicate that LPS alters 
vlPAG astrocytic glutamate uptake in a similar manner to morphine.  
Systemic administration of XPro®1595 prevented morphine tolerance 
Finally, we tested the ability of a novel, brain permeant human DN-TNF peptide 
(XPro®1595) to preserve morphine analgesia. XPro®1595 is a dominant negative TNF variant 
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with FDA IND status that selectively diminishes the inflammatory signal of soluble TNF (> 
2500-fold)192,207 in the same manner as the virally expressed DN-TNF in Experiment 1. An 
ELISA for human TNF (hTNF) revealed robust presence of hTNF in plasma, CSF, and midbrain 
tissue from animals treated with XPro®1595 (Figure 4.5c, d, and e). Indeed, midbrain levels 
strongly correlated with CSF levels of hTNF (R2 = 0.867; y = 0.76x + 0.350), indicating efficient 
transport into the brain. hTNF was not detected in Vehicle + Morphine or Vehicle + Saline 
treated animals (data not shown). No differences in baseline nociceptive thresholds or acute (Day 
1) morphine analgesia were noted between groups (Figure 4.5a). Animals pretreated with 
Vehicle + Morphine showed signs of tolerance following the third sc morphine injection, while 
animals pretreated with XPro®1595 + Morphine did not (F(3,17) = 17.046; p < 0.000). 
Administration of cumulative doses of morphine on Day 4 produced an increase in nociceptive 
thresholds in all animals tested (Figure 5b). ANOVA revealed a significant main effect of 
treatment (F(3,258) = 87.31, p < 0.0001). Pretreatment with Vehicle + Morphine resulted in a 
significant threefold rightward shift in the dose-response curve (ED50 = 8.03 mg/kg), as 
compared with Vehicle + Saline animals (ED50 = 2.31  mg/kg; p < 0.001;  Figure 4.5), indicating 
tolerance to morphine. Systemic pretreatment with DN-TNF (XPro®1595) preserved the 
antinociceptive potency of morphine (XPro + Morphine; ED50 = 3.08 mg/kg) compared with 
animals made tolerant to morphine (Vehicle + Morphine; p < 0.001). These data indicate that 
animals given systemic XPro®1595 + Morphine did not develop tolerance to morphine as 
compared with animals given Vehicle + Morphine. Together, these results support our 
hypothesis that XPro®1595 could feasibly be used in conjunction with opioid therapy to 
maintain analgesic efficacy in the clinic.  
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Systemic administration of XPro®1595 abolished morphine-induced increases in vlPAG TLR4 
and IL-1β mRNA 
TNF and TLR4 are major regulators of cytokine expression in the CNS (e.g., IL-6, IL-1β, 
and TNF), and cytokines including IL-1β and IL-6 have been implicated in morphine tolerance 
development. Our final experiment tested the hypothesis that morphine increases 
proinflammatory cytokine expression in the vlPAG via solTNF signaling. Changes in vlPAG 
TLR4 mRNA were also assayed. Quantitative reverse transcriptase PCR (qPCR) revealed that 
chronic morphine resulted in a median 49% increase in vlPAG TNF mRNA as compared with 
Vehicle + Saline treated animals (Figure 4.6a). Similar results were noted for IL-6 gene 
expression, with morphine increasing vlPAG IL-6 mRNA by 8% as compared with Vehicle + 
Saline controls. However, the increase in TNF and IL-6 gene expression was not statistically 
significant (Kruskal-Wallis, H = 4.00, 2 df, p = 0.136 and H = 1.56, 2 df; p = 0.457, 
respectively). There were no differences in IL-10 mRNA (H = 2.42, 2 df; p = 0.298). A one-way 
ANOVA on ranks indicated a significant main effect of treatment on IL-1β (Figure 4.6b) and 
TLR4 (Figure 4.6c) mRNA (H = 8.05, 2 df; p = 0.018 and H = 7.49, 2 df; p = 0.024, 
respectively).  Morphine significantly increased vlPAG IL-1β mRNA by 3,500% as compared 
with Vehicle + Saline controls, a nearly 30-fold increase as compared with the 120% increase 
noted for XPro + Saline treated controls (W = 15; p = 0.016, Figure 4.6b). Co-administration of 
systemic XPro®1595 and morphine eliminated the increase in IL-1β gene expression as these 
animals did not differ from XPro + Saline controls (W = 26; p = 0.841). Finally, post hoc 
analysis revealed a significant 53% increase in vlPAG TLR4 gene expression in Vehicle + 
Morphine treated animals as compared with XPro + Saline controls (25% decrease, W = 15; p = 
0.016). Co-administration of XPro®1595 with morphine normalized TLR4 mRNA as XPro + 
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Morphine and XPro + Saline animals did not differ (W = 17.5; p = 0.063). We used 
nonparametric statistics as our data did not reach the assumptions of normality; Vehicle + Saline 
controls had very high variability which lead to a lack of homogeneity of variance in the data. In 
combination with our previous results demonstrating a role for vlPAG TLR482, these data 
indicate that solTNF regulates gene expression of the proinflammatory cytokine IL-1β and the 
innate immune receptor TLR4, and implicate solTNF as an important mediator of vlPAG TLR4-
mediated tolerance development.  
Discussion 
The present set of experiments tested the hypothesis that vlPAG TLR4 contributes to 
morphine tolerance development via soluble TNF-dependent modulation of glutamate 
homeostasis. Here we report that (1) vlPAG microinjections of lenti-DN-TNF rescued the 
morphine-induced decrease in astrocytic glutamate transporter mRNA (GLT-1 and GLAST) in 
the vlPAG, and prevented the development of tolerance to systemically administered morphine; 
(2) vlPAG microinfusions of the TLR4 agonist LPS induced a naïve tolerance to systemic 
morphine, as previously reported82, and significantly decreased GLT-1 and GLAST mRNA in 
the vlPAG in a manner that paralleled the effects of morphine; (3) vlPAG microinjections of 
lenti-DN-TNF prevented LPS-induced tolerance to morphine, and rescued or increased vlPAG 
GLT-1 and GLAST gene expression, respectively; and (4) sequestration of solTNF with 
systemic administration of XPro®1595  prevented morphine tolerance development, and 
decreased (TLR4) and eliminated (IL-1β) morphine-induced increases in proinflammatory 
factors, and attenuated the trending increases in other cytokines (TNF, and IL-6 mRNA) in the 
vlPAG. Together, these data indicate that the development of morphine tolerance is correlated 
with increased proinflammatory gene expression and decreased astrocytic glutamate transporter 
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mRNA in the vlPAG that is TLR4 dependent. Sequestration of vlPAG soluble TNF normalizes 
these changes and prevents morphine tolerance. Together, these data are the first to isolate 
soluble TNF signaling as necessary for opioid tolerance, and the first to implicate PAG cytokines 
and PAG astrocytic glutamate transporters in morphine tolerance. 
Morphine and other opioids bind to neuronal MOR6 and hyperpolarize GABAergic 
neurons to elicit analgesia9,27-29. Indeed, opioids have a direct inhibitory effect on most MOR 
expressing neurons30 including those in the descending analgesic circuit (i.e., PAG, RVM, and 
spinal cord)9,11,30-33. MOR binding in the vlPAG hyperpolarizes GABAergic interneurons34,36, 
thereby releasing vlPAG-RVM projection neurons from local tonic inhibition36. In PAG slices, 
morphine inhibits mIPSP frequency and decreases the probability of presynaptic GABA 
release31,34. This effect is enhanced in the presence of anti-inflammatory compounds including 
cyclooxygenase inhibitors and 5-lipoxygenase inhibitors31. Indeed, microinfusion of 
cyclooxygenase inhibitors into the PAG produces robust analgesia216. Together with the present 
results, these data suggest that morphine hyperpolarization of PAG neurons is critical for opioid 
induced analgesia, and that proinflammatory signaling in the PAG opposes morphine analgesia 
by decreasing morphine hyperpolarization of GABAergic PAG interneurons.  
 In agreement with our previous findings45,82,173, here we show that tolerance to morphine 
developed rapidly. Indeed, systemic administration of one ED50 dose of morphine (5 mg/kg) for 
3 days was sufficient to induce tolerance as indicated by a significant 3-fold rightward shift in 
the morphine dose response curve. A significant decrease in vlPAG GLT-1 and GLAST mRNA 
paralleled the development of tolerance, demonstrating that chronic morphine decreases 
astrocyte-mediated glutamate uptake in the vlPAG. No change was noted in vlPAG neuronal 
EAAC1 mRNA, suggesting that chronic opioids preferentially alter astrocyte-mediated 
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glutamate homeostasis in the vlPAG. In controls, GLT-1 mRNA levels were approximately 3 
times higher than GLAST and EAAC1, suggesting that GLT-1 is the main source of glutamate 
uptake in the PAG. Chronic morphine did increase EAAC1 in the inferior colliculus, pointing to 
a potential role for opioid mediated glutamate plasticity in auditory midbrain regions217. vlPAG 
soluble TNF was necessary for the molecular and behavioral effects of chronic morphine on 
glutamate transporter expression, as DN-TNF prevented morphine-induced decreases in GLT-1 
and GLAST mRNA in the vlPAG and preserved morphine analgesia.  
The present results confirm our previous data indicating that vlPAG astrocytes contribute 
to the development of morphine tolerance 82, and complement a vast literature demonstrating a 
role for glia85 and excitatory neurotransmission62,63. Astrocytes are responsible for the majority 
of glutamate uptake in the CNS via GLT-1 and GLAST218, thereby terminating glutamatergic 
signaling219-221. A significant increase in CSF glutamate and aspartate has been reported in 
morphine-tolerant humans52, and morphine challenge increases glutamate in the CSF of 
morphine tolerant rats53. Increased glutamate uptake by GLT-1 attenuates morphine tolerance in 
mice222, further indicating a role for astrocytes. Chronic morphine also increases AMPA and 
NMDA receptor subunits54 and NMDA receptor binding55 in the rat spinal cord, while blocking 
NMDA56-61 and AMPA62,63 glutamatergic signaling attenuates tolerance. Together with our 
results, these data suggest that a breakdown in astrocyte-mediated glutamate homeostasis 
significantly contributes to opioid tolerance.  
The present studies also establish that vlPAG soluble TNF signaling is necessary for the 
decreased expression levels of vlPAG GLT-1 and GLAST mRNA and morphine tolerance. 
These findings corroborate previous studies demonstrating a role for spinal cord TNF in 
morphine tolerance54,102,106 and opioid-induced modulation of GLT-1 and GLAST102. Acute or 
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chronic intrathecal Etanercept, a decoy TNF receptor that sequesters both solTNF and tmTNF, 
attenuates tolerance to systemic morphine106 and the ensuing changes in the glutamatergic 
system54. Our data from the vlPAG complement these findings in the spinal cord, and 
demonstrate for the first time that soluble TNF, and not tmTNF signaling, mediates morphine 
tolerance development and alterations in astrocytic glutamate homeostasis.  
Our results are in contrast to previous data indicating that modulation of glutamate 
signaling in the PAG does not prevent tolerance to morphine65. Morgan and colleagues 
demonstrated that the NMDA receptor antagonist MK-801 microinjected into the ventral PAG 
(vPAG) does not prevent tolerance to intra-vPAG morphine65. However, chronic morphine 
administration does not alter NMDA receptor expression in the PAG66, indicating a need to 
investigate the involvement of alternative mechanisms of glutamate signaling in the PAG. It is 
important to note that in addition to regulating GLT-1 and GLAST expression, TNF is a major 
driver of inflammation, increasing the expression of TLR4 and other proinflammatory factors, 
including glutamate, nitric oxide and inducible nitric oxide synthase, cyclooxygenase 2, TNF, 
and IL-1β; these factors all increase neuronal excitability and contribute to opioid tolerance71. 
Indeed, TNF alters excitation of neurons in several systems. For example, TNF increases the 
density and conductance of neuronal AMPA receptors and decreases GABAA receptors in 
hippocampal slices145. Functionally, these changes increase miniature EPSCs and decrease 
miniature IPSCs145. The effects of TNF on hippocampal AMPA and GABA receptor expression 
occur via neuronal TNFRI but not TNFRII145, implicating soluble TNF. Additionally, TNF, and 
to a lesser extent IL-1β, significantly increases neuronal GluR2-lacking AMPARs in vitro144. 
While alterations in vlPAG AMPA and GABAA receptors were not investigated in the present 
study, Bobeck and colleagues recently demonstrated that chronic intra-vlPAG morphine results 
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in tolerance that is dependent on alterations in both pre- and post-synaptic GABA release42. As 
TNF can modulate many of the excitatory changes observed in the development of opioid 
tolerance, preventing solTNF signaling in the vlPAG likely decreases excitation more robustly 
than any single modulation of glutamate signaling in isolation.  
It is now clear that the innate immune receptor TLR4, but not MOR81, mediates 
morphine-induced cytokine release (including TNF)78,79,81 and the induction of tolerance. Here 
we show that behaviorally defined tolerance to morphine, and the concurrent decrease in GLT-1 
and GLAST mRNA, is mediated by vlPAG TLR4 signaling. Consistent with our previous 
findings82, vlPAG infusions of the prototypical TLR4 agonist LPS, in the absence of chronic 
morphine, resulted in behaviorally-defined tolerance, indicating that activation of vlPAG TLR4 
is sufficient to induce tolerance. Intra-vlPAG LPS also significantly decreased GLT-1 and 
GLAST mRNA in the vlPAG that was on par with the reduction noted in animals made tolerant 
by chronic systemic morphine. vlPAG LPS administration did not alter neuronal EAAC1 
mRNA, although there was a trend towards a decrease, suggesting that chronic TLR4 activation 
and systemic morphine preferentially alter astrocyte-mediated glutamate homeostasis in a similar 
manner. Together, these results suggest that vlPAG TLR4 signaling mediates the alterations in 
glutamatergic signaling induced by chronic morphine. vlPAG soluble TNF was necessary for the 
molecular and behavioral effects of chronic vlPAG LPS administration, as vlPAG DN-TNF 
attenuated LPS-induced decreases in vlPAG GLT-1 and GLAST mRNA, and preserved 
morphine analgesia. These data complement our previous results demonstrating the necessity and 
sufficiency of vlPAG TLR4 signaling in the development of morphine tolerance82 and further 
demonstrate that TLR4-mediated increases in soluble TNF signaling result in enhanced 
neuroexcitability in the vlPAG and induction of morphine tolerance. 
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XPro®1595 is a novel, brain-permeant, dominant negative TNF variant with FDA IND 
status that selectively diminishes the inflammatory signal of soluble TNF (> 2500-fold)192,207 in 
the same manner as the virally expressed DN-TNF. Here we demonstrate that systemically 
administered XPro®1595 (DN-TNF) decreased opioid-induced inflammation in the vlPAG and 
prevented morphine tolerance.  XPro®1595 administration also prevented the morphine-induced 
increase in IL-1β and attenuated the significant increase in TLR4 mRNA in the vlPAG, and 
eliminated the trending increase in TNF and IL-6 mRNA. Together, these data corroborate 
previous results indicating that TNF is a major driver of inflammation, and support XPro®1595 
as a potential addition to opioid therapy in clinical pain management. XPro®1595 may be 
preferable over current FDA approved anti-TNF biologics (Etanercept, Inflliximab, 
Adalimumab) as these drugs block both forms of TNF and are associated with encephalic 
lesions, neuritis, multiple sclerosis, and other demyelinating diseases194. 
Our results are consistent with previous studies implicating IL-1β in glutamatergic 
plasticity and opioid tolerance71. For example, opioids increase IL-1β mRNA and protein in vitro 
and in vivo223,224, and modulation of spinal IL-1β attenuates opioid tolerance development225. IL-
1β also increases neuronal GluR2-lacking AMPAR expression144, contributing to an increased 
excitatory environment. In the present study, opioid tolerance was accompanied by a significant 
increase in vlPAG TLR4 mRNA, indicating that chronic morphine primes vlPAG glia to over-
respond to subsequent morphine challenges by increasing gene expression of the receptor 
substrate for opioid-mediated inflammation (TLR478,81). The simultaneous increase in IL-1β and 
TLR4 mRNA is of note as these factors share a similar signaling domain (Toll/IL-1 receptor 
(TIR) domain) that associates with MyD88 to induce robust inflammation226.   
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Contrary to what has been noted in the spinal cord, chronic morphine did not increase 
vlPAG TNF mRNA, however, there was a trend towards an increase. TNF is found in very low 
concentrations in the CNS (femtomolar to picomolar range), and binds with high affinity to a 
relatively small number of receptors227. In vitro, TNF protein is significantly increased by the 
TLR4 agonist LPS, in a TACE-dependent manner, 30 minutes following LPS application228. In 
vivo, acute intrathecal morphine analgesia is reduced by TNF within 5 minutes of morphine 
administration74, suggesting that morphine leads to the quick release of soluble TNF protein via 
TACE-mediated cleavage of tmTNF. As TNF is primarily responsible for initiating the 
production of other proinflammatory cytokines71, morphine signaling through TLR4 may induce 
rapid cleavage of tmTNF to solTNF protein and stimulate the production of IL-1β and TLR4 
mRNA to modulate glutamate homeostasis. TACE inhibition reduces TNF, IL-6, and IL-1α in 
equine species in vivo and in human cells in vitro to reduce pain229,230. Together with these 
dissertation results (Chapter 1-4), these findings suggest that TACE inhibition may preserve 
morphine analgesia and prevent tolerance development in the vlPAG by preventing TLR4-
mediated soluble TNF signaling. A trend towards an increase in vlPAG IL-6 mRNA was also 
noted, and there was no morphine-induced alteration in the anti-inflammatory cytokine IL-10. 
Together these data indicate that chronic morphine induces alterations in vlPAG inflammation 
that parallel and diverge from what has been noted in other CNS regions.  
In summary, the development of morphine tolerance was paralleled by increased 
proinflammatory gene expression and decreased astrocytic glutamate transporter mRNA in the 
vlPAG. Our results further show that exclusive sequestration of solTNF prevents opioid induced 
neuroinflammation, alterations in glutamate homeostasis, and morphine tolerance, indicating that 
tmTNF signaling (TNFRI and TNFRII) does not contribute to opioid tolerance development. As 
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TNFRII is protective against glutamate excitotoxicity231, TNFRII signaling may be a critical 
countermeasure to opioid-induced neuroexcitability that is important to preserve. These data are 
also the first to demonstrate a direct role for PAG cytokines in tolerance development. Chronic 
vlPAG LPS resulted in behavioral and molecular phenotypes that paralleled morphine-treated 
animals, suggesting that vlPAG innate immune receptor signaling mediates the proinflammatory 
effects of opioids. Finally, our results support XPro®1595 as a potential anti-inflammatory gene 
therapy to complement opioid therapy in clinical pain management, as XPro®1595 injected 
systemically was efficiently transported to midbrain tissue, normalized vlPAG 
neuroinflammation, and effectively preserved behaviorally defined morphine analgesia. 
Together, these data suggest that the ability of morphine to hyperpolarize neurons in the PAG is 
critical for opioid induced analgesia, and that proinflammatory signaling in the PAG can oppose 
morphine analgesia by decreasing the ability of morphine to hyperpolarize GABAergic PAG 
interneurons.  
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Chapter 4 Tables 
Table 4.1 Summary of morphine ED50s following chronic morphine administration. 
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Table 4.2 Summary of qPCR primer specifications. 
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Chapter 4 Figures 
Figure 4.1 Summary of acute morphine analgesia and morphine tolerance following 
vlPAG soluble TNF sequestration. 
Viral vector-mediated sequestration of soluble TNF in the vlPAG prevents the development of 
tolerance to morphine. (a) Schematic of lenti-GFP and lenti-DN-TNF lentiviral vectors. Both 
lenti-GFP and lenti-DN-TNF vectors contain a chicken b-actin cytomegalovirus 
enhancer/promoter (CAG), b-globin intron, a central polypurine tract of HIV-1 (ppt), a 
woodchuck hepatitis virus posttransciptional response element (WPRE), and a self-inactivating 
deletion in the 3’ LTR. The lenti-DN-TNF vector contains an internal ribosome entry site (IRES) 
for GFP expression following the sequence for pro-human DN-TNF (A145R/I97T). (b) 
Representative locations of lenti-GFP (circles) and lenti-DN-TNF (squares) microinfusions in the 
caudal vlPAG (Bregma – 8.03), and representative light and FITC images of injection location 
and GFP expression from the same section. Dotted lines indicate aqueduct location. (c) Paw 
withdrawal latency (s) during nociceptive testing on day 1 (D1) and day 3 (D3) at baseline and 
15 minutes post saline or morphine injection in groups pre-treated with lenti-GFP or lenti-DN-
TNF. Baseline nociceptive thresholds did not differ on D1 or D3. Lenti-GFP + Saline (n = 4; 
black circles) and lenti-DN-TNF + Saline (n= 5; black squares) groups do not differ at any time 
point.  There was no difference in the analgesic potency of morphine between lenti GFP (n = 10) 
and lenti-DN-TNF (n = 10; red symbols) treated animals on D1 (p = 0.84). The antinociceptive 
potency of morphine was significantly lower in animals pretreated with lenti-GFP as compared 
with lenti-DN-TNF (p < 0.000) on D3. Data are represented as mean PWL + SEM. (d) Paw 
withdrawal latency (s) during cumulative morphine injections on D4 in animals pretreated with 
lenti-GFP + Saline (black circles), lenti-GFP + Morphine (red circles), lenti-DN-TNF + Saline 
(black squares), and lenti-DN-TNF + Morphine (red squares). Pretreatment with lenti-GFP + 
Morphine resulted in a three fold rightward shift in the dose-response curve compared with lenti-
GFP + Saline controls (p = 0.01), indicating tolerance to morphine. Sequestration of vlPAG 
solTNF prevented tolerance as lenti-DN-TNF + Morphine animals did not differ from lenti-GFP 
+ Saline controls (p = 0.15). Data are represented as mean PWL + SEM. 
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Figure 4.2 Summary of morphine tolerance following vlPAG LPS and solTNF 
sequestration.  
Aq stands for aqueduct. Viral vector-mediated sequestration of soluble TNF in the vlPAG 
prevents the development of morphine tolerance induced by vlPAG LPS microinfusions. (a) 
Representative locations of lenti-GFP (circles) and lenti-DN-TNF (squares) microinfusions in the 
vlPAG (Bregma -8.04), and representative FITC photomicrograph of GFP expression in the 
vlPAG. Aq indicates the location of the aqueduct. (b) Paw withdrawal latency (s) during 
cumulative morphine injections in animals pretreated with lenti-GFP + PAG Saline (n = 4; black 
circles), lenti-GFP + PAG LPS (n = 4; red circles), lenti-DN-TNF + PAG Saline (n = 6; black 
squares), and lenti-DN-TNF + PAG LPS (n = 9; red squares). Pretreatment with lenti-GFP + LPS 
resulted in a significant rightward shift in the dose-response curve compared with lenti-GFP + 
PAG Saline controls (p = 0.015), indicating tolerance to morphine. Sequestration of vlPAG 
solTNF prevented tolerance as lenti-DN-TNF + PAG LPS animals did not differ from lenti-DN-
TNF + PAG Saline controls (p = 0.067). Data are represented as mean PWL + SEM. 
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Figure 4.3 Summary of vlPAG glutamate transporter mRNA following chronic 
morphine and vlPAG sequestration of solTNF. 
Viral vector-mediated sequestration of soluble TNF in the vlPAG prevents the morphine-induced 
decrease in astrocytic glutamate transporter mRNA. (a) Representative photomicrographs (left 
inset) of GLT-1 specific hybridization in the caudal PAG (Bregma -8.04) of animals treated with 
lenti-GFP + Saline (left) and lenti-GFP + Morphine (right). Aq denotes the aqueduct and the red 
box represents the sampling region. Mean GLT-1 specific hybridization in the inferior colliculus 
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(right inset) did not differ between groups (p = 0.241). Mean GLT-1 specific hybridization in the 
caudal vlPAG (main graph). Morphine (once a day for 3 days) significantly decreased vlPAG 
GLT-1 mRNA as compared with lenti-GFP + Saline controls (p = 0.004). Sequestration of 
soluble TNF in the vlPAG prevented the morphine-induced decrease in GLT-1 mRNA as lenti-
DN-TNF + Morphine animals did not differ from lenti-GFP + Saline controls (p = 0.128). (b) 
Representative photomicrographs (left inset) of GLAST specific hybridization in the caudal PAG 
(Bregma -8.04) of animals treated with lenti-GFP + Saline (left) and lenti-GFP + Morphine 
(right). Mean GLAST specific hybridization in the inferior colliculus (right inset) did not differ 
between groups (p = 0.249). Mean GLAST specific hybridization in the caudal vlPAG (main 
graph). Morphine (once a day for 3 days) significantly decreased vlPAG GLAST mRNA as 
compared with lenti-GFP + Saline controls (p < 0.000). Sequestration of soluble TNF in the 
vlPAG prevented the morphine-induced decrease in GLAST mRNA as lenti-DN-TNF + 
Morphine animals did not differ from lenti-GFP + Saline controls (p = 0.494). (c) Representative 
photomicrographs (left inset) of neuronal EAAC1 specific hybridization in the caudal PAG 
(Bregma -8.04) of animals treated with lenti-GFP + Saline (left) and lenti-GFP + Morphine 
(right). Mean EAAC1 specific hybridization was increased in the inferior colliculus (right inset) 
in animals treated with lenti-GFP + Morphine as compared with lenti-GFP + Saline controls (p < 
0.000). Mean EAAC1 specific hybridization in the caudal vlPAG (main graph) did not differ 
between groups (p = 0.466). Specific hybridization is reported as the mean disintegrations per 
minute per milligram of tissue (dpm/mg) + SEM; n = 4/6 per group).  
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Figure 4.4 Summary of vlPAG glutamate transporter mRNA following chronic 
vlPAG LPS and sequestration of solTNF. 
Viral vector-mediated sequestration of soluble TNF in the vlPAG prevents or attenuates the LPS-
induced decrease in astrocytic glutamate transporter mRNA. (a) Representative 
photomicrographs (left inset) of GLT-1 specific hybridization in the caudal PAG (Bregma -8.04) 
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of animals treated with lenti-GFP + PAG Saline (left) and lenti-GFP + PAG Morphine (right). 
Aq denotes the aqueduct and the red box represents the sampling region. Mean GLT-1 specific 
hybridization in the inferior colliculus (right inset) was decreased in animals treated with lenti-
GFP + PAG LPS as compared with lenti-GFP + PAG Saline controls (p = 0.015). Mean GLT-1 
specific hybridization in the caudal vlPAG (main graph). LPS (once a day for 3 days) 
significantly decreased vlPAG GLT-1 mRNA as compared with lenti-GFP + PAG Saline 
controls (p = 0.005). Sequestration of soluble TNF in the vlPAG prevented the morphine-
induced decrease in GLT-1 mRNA as lenti-DN-TNF + PAG LPS animals did not differ from 
lenti-GFP + PAG Saline controls (p = 0.723). (b) Representative photomicrographs (left inset) of 
GLAST specific hybridization in the caudal PAG (Bregma -8.04) of animals treated with lenti-
GFP + PAG Saline (left) and lenti-GFP + PAG LPS (right). Mean GLAST specific hybridization 
in the inferior colliculus (right inset) did not differ between groups (p = 0.347). Mean GLAST 
specific hybridization in the caudal vlPAG (main graph). LPS (once a day for 3 days) 
significantly decreased vlPAG GLAST mRNA as compared with lenti-GFP + Saline controls (p 
= 0.002). Sequestration of soluble TNF in the vlPAG (lenti-DN-TNF + LPS) attenuated, but did 
not eliminate, the LPS-induced decrease in GLAST mRNA as compared with lenti-GFP + PAG 
Saline controls (p = 0.044). (c) Representative photomicrographs (left inset) of neuronal EAAC1 
specific hybridization in the caudal PAG (Bregma -8.04) of animals treated with lenti-GFP + 
PAG Saline (left) and lenti-GFP + PAG LPS (right). Mean EAAC1 specific hybridization in the 
inferior colliculus (right inset) did not differ (p = 0.592). Mean EAAC1 specific hybridization in 
the caudal vlPAG (main graph) did not differ between groups (p = 0.166). Specific hybridization 
is reported as the mean disintegrations per minute per milligram of tissue (dpm/mg) + SEM; n = 
4/6 per group). 
 
103 
Figure 4.5 Summary of acute morphine analgesia and morphine tolerance following 
systemic XPro1595 and morphine.  
Systemic administration of XPro®1595 prevents the development of tolerance to morphine. (a) 
Paw withdrawal latency (s) during nociceptive testing on day 1 (D1) and day 3 (D3) at baseline 
and 15 minutes post saline or morphine injection in groups pre-treated with XPro®1595 or 
Vehicle (saline). Baseline nociceptive thresholds did not differ on D1 or D3. Vehicle + Saline (n 
= 8; black circles) and XPro + Saline (n= 8; black squares) groups do not differ at any time point.  
There was no difference in the analgesic potency of morphine between Vehicle (n = 11) and 
XPro®1595 (n = 11; red symbols) treated animals on D1 (p = 0.84). The antinociceptive potency 
of morphine was significantly lower in animals pretreated with Vehicle as compared with 
XPro®1595 (p < 0.000) on D3. Data are represented as mean PWL + SEM. (b) Paw withdrawal 
latency (s) during cumulative morphine injections on D4 in animals pretreated with Vehicle + 
Saline (black circles), Vehicle + Morphine (red circles), XPro + Saline (black squares), and XPro 
+ Morphine (red squares). Pretreatment with Vehicle + Morphine resulted in a significant 
rightward shift in the dose-response curve compared with Vehicle + Saline controls (p < 0.000), 
indicating tolerance to morphine. Sequestration of solTNF (XPro + Morphine) prevented 
tolerance as compared with Vehicle + Morphine controls (p < 0.001). Data are represented as 
mean PWL + SEM. (c, d, e) Midbrain, CSF, and plasma expression of DN-TNF in animals 
treated with XPro®1595 as measured with ELISA for human TNF (n= 3/6 per group). 
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Figure 4.6 Summary of cytokine and TLR4 mRNA in the vlPAG following chronic 
systemic XPro1595 and morphine.  
Systemic administration of XPro®1595 prevents morphine induced increases in vlPAG IL-1β 
and TLR4 mRNA. (a) Tnf, (b) Il1β, (c) Tlr4, (d) Il6, and (e) Il10 mRNA levels relative to the 
housekeeping gene Gapdh, normalized to the Vehicle + Saline group in the vlPAG of animals 
treated with Saline + Morphine, XPro + Saline, and XPro + Morphine. (b) Morphine 
significantly increased vlPAG IL-1β (p= 0.018) and (c) TLR4 (p = 0.024) mRNA in the vlPAG. 
Systemic XPro®1595 prevented the morphine induced increase in IL-1β and TLR4 mRNA as 
these animals did not differ from XPro + Saline treated controls (p = 0.841 and p = 0.063, 
respectively). Data are represented as median % change from Vehicle + Saline controls; n = 5 
per group. (f) All primer pairs produced amplicons of appropriate size as compared to the control 
DNA ladder. Representative schematic of vlPAG tissue punch location (top left). PCR amplicons 
from each gene of interest were run on a 2% agarose gel (main photomicrograph) to demonstrate 
primer specificity. All genes localized to regions appropriate to their predicted size. 
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vlPAG astrocyte activity significantly contributes to morphine tolerance. 
Chronic pain, defined as pain lasting more than three months, impacts approximately 
55% of the population over the age of 20. Opioid-based narcotics are the most prevalent 
therapeutic treatment for the management of pain. Although morphine is amongst the most 
effective analgesics available, prolonged morphine treatment results in decreased analgesic 
efficacy (i.e., tolerance), resulting in the requirement for steadily larger doses of opiates for the 
maintenance of analgesic efficacy3. Many mechanisms have been proposed to account for opioid 
tolerance, including MOR decoupling, internalization, and/or down-regulation of MORs136,137. 
However, in comparison to other opioids (e.g., DAMGO, fentanyl6), morphine does not result in 
MOR internalization, and is remarkably weak in terms of decreasing G-protein signaling and 
receptor desensitization232,233. Indeed, chronic morphine increases G-protein efficiency in the 
vlPAG42. Together with our data (Chapter 2 – 4), these data suggest other mechanisms contribute 
to morphine tolerance at the level of the midbrain PAG.  
Non-opioid receptor-related hypotheses, including alterations in neuronal excitability and 
glutamatergic signaling have also been proposed. For example, upregulation of NMDA and 
AMPA receptor function62,138-140, down-regulation of glutamate transporters53,54,141,142, and 
production of nitric oxide (NO; a known mediator of NMDAR function)234 have all been shown 
to contribute to tolerance. However, it is now becoming increasingly clear that ‘activated’ glia 
(microglia and astrocytes; the ‘non’-neuronal cells of the CNS) mediate many of these effects, as 
well as other adaptations that contribute to morphine tolerance.  
Under basal conditions, microglia and astrocytes survey the environment for pathogens, 
including viruses and bacteria. Disturbances in homeostasis results in the rapid activation of glia, 
evidenced by a profound shift in morphology that can be easily visualized using 
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immunohistochemistry for OX42 (CD11b; microglia) and glial fibrillary acidic protein (GFAP; 
astrocytes)127. Glial activation also results in the increased production and release of pro-
inflammatory cytokines (including IL-1β, IL-6, and TNFα), chemokines, ATP, excitatory amino 
acids, and NO, all of which increase the excitability of nearby neurons86,93. Indeed, glially-
derived cytokine release results in increases in the number and conductance of AMPA144,145 and 
NMDA146 receptors, decreases in astrocytic glutamate transporter proteins85, and down-
regulation of GABA receptors145. Microglia derived IL-1β and TNF bind to receptors on 
astrocytes, resulting in the further release of IL-1β, IL-6, and TNF86. These cytokines actively 
oppose the analgesic actions of morphine reducing pain relief71.  
Acute and chronic morphine administration activates microglia and astrocytes28, 48, 49, 
72,86,91-93,119, with the degree of glial activation increasing with duration of opioid treatment81. 
Increased opioid consumption and the ensuing glial activation ultimately results in the opposition 
of morphine analgesia and the development of morphine tolerance. Studies by Song and Zhou 
(2001), as well as others, have shown that inhibition of spinal glia activation with general glial 
metabolic inhibitors results in a partial attenuation in morphine tolerance71,73,84,86,87. Interestingly, 
spinal glia activation induced by other stimuli, such as neuropathic pain or lipopolysaccharide 
(LPS; a potent TLR4 agonist) administration, also reduces the analgesic efficacy of morphine88. 
Complementing literature from the spinal cord and RVM, here we demonstrate that glial 
activation within the PAG is critical for the development of morphine tolerance. First, we found 
that administration of a single ED50 dose of morphine once a day for 3 days (but not 
administration of a single ED50 dose of morphine once a day for only 1 day; Chapter 2) 
significantly activated both microglia and astrocytes in the PAG, as indicated by a 2-fold 
increase in OX42 and GFAP protein levels (when measured 24 hours later). OX42 and GFAP 
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expression within the PAG paralleled the development of morphine tolerance such that animals 
that were tolerant to the antinociceptive effects of morphine had the highest OX42 and GFAP 
immunoreactivity (Chapter 2 and 3). Persistent inflammatory hyperalgesia induced by 
intraplantar administration of complete Freund’s adjuvant (CFA), significantly attenuated the 
development of morphine tolerance, and no significant differences were noted in vlPAG glial 
cell activation for CFA + Saline and CFA + Morphine treated animals versus controls (Handled 
+ Saline; Chapter 2). These data mirror clinical data indicating that peripheral inflammatory pain 
delays the development of tolerance132,153-155, and suggest that there is something unique about 
persistent inflammatory pain that blocks morphine from activating glia.  
Shortly after publication of Chapter 2, Morgan and colleagues reported that intraplantar 
CFA prevents tolerance to chronic intra-vlPAG microinjections of morphine235. These data 
corroborate our results, and suggest that pain-induced changes in the vlPAG are responsible for 
the preservation of opioid analgesia during a persistent inflammatory pain state. No PAG glia 
activation was noted following administration of CFA alone (Chapter 2). These results suggest 
that peripheral pain site-specifically prevents glial cell activation in the PAG, and are in contrast 
to several studies at the level of the spinal cord and medulla (i.e., RVM) demonstrating that 
peripheral pain, including CFA163-166,176, peripheral neuropathy71,90,94,127,165,167,168, formalin169, 
and spinal nerve ligation170 induce significant glia activation. However, given the unique roles of 
the PAG and spinal cord in pain modulation and pain facilitation, respectively, it is not entirely 
surprising that there would be differential pain-induced regulation of glial activation in these two 
sites. Chronic constriction of nerves (chronic constriction injury; CCI) induces robust 
hyperalgesia and also induces robust increases in RVM and spinal cord microglia and astrocyte 
activity176. CCI-induced increases in pain sensitivity are attenuated by glial cell inhibitors 
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(propentofylline, minocycline, and fluorocitrate) injected intrathecally (at doses identical to 
Chapter 3 studies), indicating that pain induces glial cell activity at the level of the spinal cord 
and RVM, but not at the level of the PAG.  
Interestingly, neuropathic pain is thought to result from nerve damage and the slow death 
of neurons89, and burn pain induces robust inflammation108,236-238. Cell death increases following 
neuropathic pain238-240 and burn pain236, and cell death is regulated, in part, by TLR4 and TNF 
signaling71,86,93,120,127,241. Cell death results in the release of cytokines (TNF, IL-1β, IL-6)88,121, 
alarmins (heat shock proteins and fragments of self DNA that indicate nuclear cell damage), 
reactive oxygen species (nitric oxide synthase; NOS, inducible nitric oxide synthase iNOS, and 
nitric oxide; NO), and other proinflammatory factors (e.g., heat shock proteins) that activate glia, 
excite neurons, and prevent morphine analgesia89. Glia regulate all of these effects via TLR4 
signaling, and blocking glia (particularly TNF) decreases excitotoxicity and increases morphine 
efficacy in the clinic112 and in the laboratory (Chapter 2 – 4)89. Crucially, neuropathic pain and 
burn pain induce more inflammation than other painful conditions18,108,127,238,242,243, and morphine 
is not an effective acute or long-term analgesic for the treatment of neuropathic pain or burn pain 
in the clinic88. Together with our data, these data suggest that certain types of pain facilitate 
neuroinflammation (neuropathic and burn pain) more robustly than others (CFA and formalin) to 
rapidly increase neuronal excitability and prevent the inhibitory effects of morphine. This 
positive feedback loop of neuroinflammation is partially regulated by TLR4 and TNF241. Further 
investigation of neuronal death markers in the PAG would contribute to our understanding of 
how neurons fit in to this puzzle.  
Together, these studies suggest that persistent inflammatory pain elicits differential glial 
responses in a CNS region-dependent manner, and prevents morphine-induced increases in 
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vlPAG glial cell activity. While we did not investigate the mechanisms whereby pain inhibits 
vlPAG glia to preserve analgesia, evidence suggests a role for endogenous cannabinoids. 
Cannabinoids are released within the PAG during peripheral pain156, and cannabinoid receptors 
are robustly expressed within the vlPAG, with approximately 32% of cannabinoid receptor 1 
(CB1)-expressing neurons also expressing MOR157. Functionally, intra-PAG administration of a 
CB1 agonist enhances morphine analgesia158, and systemic administration of cannabinoids, along 
with morphine, leads to the attenuation of morphine tolerance158-160.  
Endocannabinoids possess potent anti-inflammatory properties161, which would likely 
block the activation of glia. Indeed, systemic administration of the cannabinoid receptor agonist 
WIN 55,212-2 prevents morphine- or pain-induced glia activation and decreases the release of 
the proinflammatory cytokines IL-1β, IL-6, and TNF in the spinal cord159,162.  Recent data also 
indicate that cannabinoids and opioids synergize in the vlPAG to increase opioid-mediated 
analgesia158,244 suggesting that cannabinoid signaling in the PAG inhibits glia to enhance opioid 
analgesia. Together, our results complement data from the spinal cord and RVM demonstrating 
increased OX-42 and GFAP following chronic morphine. Additionally, we hypothesize that pain 
leads to the release of endogenous cannabinoids (anandamide) in the vlPAG156,245, and that 
cannabinoids suppress glia activity to prolong the efficacy of opioids (Chapter 2). This 
hypothesis has not been tested. However, preliminary data from an incomplete collaboration with 
Dr. Heather Bradshaw246-251, demonstrated that CFA induced the robust release of anandamide 
and 2-arachidonoylglycerol (2-AG) in the vlPAG (personal communication/side project).  
Additionally, Dr. Bradshaw’s analysis revealed that this effect was greater in females, 
suggesting that cannabinoids may mediate analgesia in females, while morphine is not 
effective45,114,123,252,253. These hypotheses remain to be tested. 
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vlPAG microinfusions of the general glial cell inhibitor propentofylline or the astrocyte 
inhibitor fluorocitrate significantly attenuated both morphine-induced vlPAG glial cell activation 
and tolerance (Chapter 3). While minocycline significantly attenuated microglial cell activation 
in the vlPAG, morphine tolerance was not affected, suggesting that vlPAG astrocytes may be 
more critical for the maintenance, and not initiation, of tolerance. These data are in contrast to 
results from the spinal cord demonstrating that inhibition of either astrocytes72 or microglia96 in 
isolation attenuates morphine tolerance to morphine. Chronic intrathecal morphine increases 
microglial p38 MAPK to induce tolerance to morphine, and pretreatment with intrathecal 
minocycline partially restores analgesia96. These data, in combination with data from Chapter 2 
demonstrating that CFA does not increase vlPAG glia activity as it does in the spinal cord, 
indicate that overlapping and distinct mechanisms underlie glia-mediated tolerance in the CNS. 
In combination with data from the spinal cord and RVM, our data indicate that 
neuroinflammation contributes to morphine tolerance at every level of the descending pain 
modulatory circuit.   
vlPAG TLR4 is necessary and sufficient for morphine tolerance 
It is well established that morphine activates glia and that glia contribute to morphine 
tolerance. However, it was not until 2010 that the mechanism by which morphine activates glia 
was discovered. At that time, the innate immune receptor, TLR4, was shown to bind opioids like 
morphine and mediate glial cell activation78. TLR4 is found primarily on microglia, and to a 
lesser degree on astrocytes, but not neurons99,100. TLR4 recognizes the endotoxin 
lipopolysaccharide (LPS; the prototypical TLR4 agonist), endogenous danger signals including 
“alarmins” (e.g., fragments of self DNA in the extracellular space that indicate cell nucleus 
damage), and certain xenobiotics including both synthetic (e.g., morphine, naloxone, oxycodone, 
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buprenorphine, fentanyl78) and endogenous (e.g., M3G79) opioids. Interestingly, MOR binds 
M6G, but not M3G 6. Conversely, TLR4 binds M3G but not M6G79,89,254. Unlike MOR, which 
only binds the (-)-stereoisomer of opioids, TLR4 binds opioid agonists and antagonists in a non-
stereoselective fashion that maintains their agonistic and antagonistic properties at TLR478. 
TLR4 agonists, including opioids and LPS, bind to the MD2 region of TLR4 resulting in 
activation of three separate signaling cascades; the PI3K/Akt, NFkB, and the MAPK pathway81. 
The former results in cell motility and apoptosis and the latter two pathways are responsible for 
the production of proinflammatory substances such as cytokines.  
It is now clear that TLR4 signaling contributes to the development of morphine 
tolerance78. Recent in vivo and in vitro data demonstrate that the innate immune receptor TLR4, 
but not MOR81, mediates morphine-induced cytokine release (including TNF)78,79,81. Chronic 
morphine increases TLR4 mRNA expression (Chapter 4)79,255 and downstream products of the 
TLR4 signaling cascade (e.g., IL-1β; Chapter 4), and systemic TLR4 antagonists attenuate 
tolerance to systemic morphine78. Results from Chapter 3 further elucidate the mechanisms by 
which morphine alters glia activity, and indicate that vlPAG glia regulate morphine tolerance 
development via TLR4 signaling. For the first time, we demonstrate expression of the TLR4 co-
receptor myeloid differentiation factor 2 (MD2) in the PAG, indicating the presence of TLR4. 
MD-2 immunoreactivity was significantly denser in PAG regions important for morphine 
analgesia (lateral and ventrolateral PAG) as compared with other subnuclei (dorsal PAG), 
indicating that morphine may preferentially activate glia in the vlPAG. Indeed morphine-induced 
OX-42, Iba1, and GFAP expression is most robust in ventral PAG regions (unpublished 
observations). vlPAG microinfusions of TLR4 antagonists, including (+)-naloxone, dose-
dependently prevented tolerance to systemic morphine, and vlPAG microinfusions of TLR4 
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agonists (in the absence of morphine) dose-dependently produced a naïve tolerance to 
subsequent challenge doses of morphine, as indicated by a significant 3-fold rightward shift in 
the morphine dose-response curve (Chapter 3). Together these data are the first to identify a CNS 
locus through which TLR4 modulates opioid tolerance, and indicate that vlPAG TLR4 signaling 
is necessary and sufficient for the development of morphine tolerance. It is important to note that 
studies demonstrating the necessity of MOR signaling in tolerance development using ‘opioid-
specific’ ligands need to be re-examined, as TLR4 binds several of these ligands in a manner that 
maintains their agonistic and antagonistic properties78. 
Using a model of persistent inflammatory pain (CFA) we also demonstrated that systemic 
antagonism of TLR4 with (+)-naloxone potentiated the antihyperalgesic effects of acute 
morphine. These data suggest that while one 24 hour pretreatment with morphine is not 
sufficient to increase vlPAG glial cell activity in the absence of pain (Chapter 2), acute morphine 
induces TLR4 signaling that counteracts the acute antihyperalgesic potency of opioids (Chapter 
3). These results are the first to demonstrate that pharmacological manipulations that 
preferentially target TLR4 improve the analgesic potency of acute morphine, and complement 
previous studies demonstrating potentiation of acute opioid antinociception by TLR4 antagonism 
in the absence of pain 78,79. Together with our results from Chapter 2, these data indicate that in 
the absence of pain, morphine is viewed as a pathogen in the CNS, resulting in the activation of 
the innate immune system via vlPAG TLR4 to contribute to opioid tolerance. Indeed, recent data 
indicate that morphine induces neuroinflammation via the same mechanisms as the endotoxin 
LPS81.  As morphine activates vlPAG glia more rapidly in the absence of pain (Chapter 2), the 
remainder of the experiments in this dissertation focused on chronic morphine administration in 
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the absence of pain in order to elucidate the mechanisms whereby vlPAG TLR4 contributes to 
morphine tolerance.  
vlPAG TLR4 modulates morphine tolerance via soluble TNF signaling 
While TNF contributes to morphine-induced inflammation and the development of 
morphine tolerance at the level of the spinal cord72-74,76,84-87,93,111,112, remarkably, no studies have 
investigated the role of TNF signaling within the vlPAG, and very few studies have directly 
tested the role of TNF in isolation54,102,106. Additionally, the specific roles of the two natural 
forms of TNF (tmTNF and solTNF) have not been dissected. Glia activation by opioids induces 
the production of the cytokines IL-1β, IL-6, and TNF, as well as neuroecitotoxic free radicals 
(NO, NOS, iNOS); these signaling factors have all been implicated in opioid tolerance71. IL-1β 
and TNF binds to their target receptors on astrocytes and microglia resulting in the further 
release of proinflammatory factors (e.g., IL-1β, IL-6, TNF, ATP, nitric oxide synthase; NOS, and 
brain derived neurotrphic factor; BDNF); this effectively induces a positive feedback loop of 
neuroinflammation71,85,88,89. BDNF binds to its neuronal receptor TrkB, which further contributes 
to neuronal excitability by initiating a depolarizing shift in anion reversal potential and 
increasing intracellular Cl- such that GABA binding becomes depolarizing256. BDNF also 
upregulates AMPA subunits and the NMDAR subunit NR2A257,258. These subunits have been 
referred to as ‘anti-opioid subunit’ due to the fact that NR2A knock-out mice do not develop 
morphine tolerance197. Together, these data indicate that morphine induced glial activation 
results in the release of an overwhelming number of factors that contribute to morphine 
tolerance.  
Products released from neurons following chronic morphine administration can also act 
on glia to result in the release of cytokines, suggesting substantial proinflammatory wind-up with 
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chronic morphine exposure. Indeed, repeated morphine administration causes neurons to release 
fractalkine and NO84. Fractalkine is a chemokine (like a cytokine that controls immune cell 
motility) that is only produced by neurons. The fractalkine receptor (CX3CR1) is only found on 
glia. Binding results in robust inflammation suggesting neuron-driven inflammatory wind-
up84,166,259-261. NO can cause activation of microglial p38 MAPK, and the release of IL-1β, IL-6, 
TNF, ATP, glutamate, prostaglandins, cholecystokinin (CCK), cyclooxygenase (COX), and 
further excitation of astrocytes88,261. COX is a precursor for prostaglandin production, and both 
prostaglandins104 and spinal and vlPAG CCK67,262,263 have all been shown to contribute to 
morphine tolerance.  These results suggest that opioid actions at TLR4 and MOR synergize and 
result in a robust positive-feedback loop of neuroinflammation, and a concurrent increase in the 
excitability of neurons that opposes the hyperpolarizing effects of morphine, and contributes to 
tolerance.  
Corroborating a vast body of work in the spinal cord, here we demonstrate that tolerance 
to systemic morphine was accompanied by increased proinflammatory cytokine expression (IL-
1β, TNF, and IL-6) in the vlPAG (Chapter 4). Additionally, chronic morphine significantly 
increased vlPAG TLR4 mRNA confirming previous results suggesting that chronic morphine 
induces an increase in the immune receptor substrate to which it binds, thereby priming glia to 
over-respond to subsequent opioid exposures255. Morphine tolerance was also accompanied by a 
significant decrease in astrocytic glutamate transporter mRNA (GLT-1 and GLAST) in the 
vlPAG. Neuronal glutamate transporter mRNA (EAAC1) was not affected by chronic morphine 
administration, suggesting that opioids preferentially alter vlPAG astrocytic glutamate uptake to 
oppose the hyperpolarizing effects of morphine, and lead to tolerance. Chronic intra-vlPAG 
microinjections of the TLR4 agonist LPS (in the absence of morphine) mimicked the effects of 
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morphine on GLT-1 and GLAST in the vlPAG (Chapter 3), suggesting that TLR4 mediates the 
inflammatory effects of chronic morphine. These results are consistent with previous studies 
demonstrating that cytokines increase neuronal excitability. Indeed, in vitro and in vivo54,144-146 
studies have reported that cytokines increase the number and conductance of AMPA and NMDA 
receptors, decrease astrocytic glutamate transporter proteins (GLT-1 and GLAST) 53,54,200, 
decrease GABA receptors and GABA currents 145, and increase presynaptic release of 
neurotransmitters71.  
The inhibitor protein dominant-negative TNF (DN-TNF) is a well-characterized variant 
of native human TNF that has been engineered to effectively sequester native solTNF and 
preclude it from initiating signaling through TNFRI by preventing receptor binding207. The use 
of DN-TNF to manipulate solTNF signaling is highly advantageous in that it spares the 
beneficial effects mediated by the transmembrane TNF (tmTNF) signal192,207. Using a lentiviral 
vector encoding dominant negative TNF (DN-TNF) or a brain-permeable DN-TNF peptide 
(XPro®1595), we demonstrate that vlPAG sequestration of soluble TNF (solTNF) abolishes 
tolerance to systemic morphine as well as naïve tolerance to morphine induced by intra-vlPAG 
injections of the TLR4 agonist LPS. vlPAG injections of lenti-DN-TNF also prevented the 
morphine-induced decreases in GLT-1 and GLAST, and systemically injected XPro®1595 
prevented the morphine-induced increase in IL-1β and TLR4 mRNA in the vlPAG, and 
eliminated the trending increase in TNF and IL-6 mRNA. These results complement work from 
Shen and colleagues demonstrating that chronic intrathecal morphine induces tolerance that is 
accompanied by decreases in spinal GLT-1 and GLAST, and increases in AMPA and NMDA 
receptor subunits. These authors further showed that one intrathecal injection of the general TNF 
decoy receptor Etanercept was sufficient to rescue morphine analgesia in morphine tolerant 
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mice, and prevent morphine-induced alterations in glutamatergic signaling54,102. Our results are 
consistent with this work, and indicate for the first time that solTNF (TNFRI), and not tmTNF 
(TNFRI and TNFRII) signaling, is necessary for morphine tolerance (Chapter 4).  
Our data are also novel in that we identify a neural locus through which TLR4 
contributes to morphine tolerance, and indicate that TLR4-induced soluble TNF signaling 
(through TNFRI) is responsible for the anti-analgesic effects of morphine-TLR4 binding. 
Together, these data support our working hypothesis and indicate that morphine binds to TLR4 
within the vlPAG, leading to the release of solTNF. Our results further suggest that solTNF 
mediates morphine tolerance in the PAG via TNFRI signaling and augmentation of glutamate 
homeostasis (Figure 1.2). Given that PAG-mediated analgesia depends largely on the ability of 
opioids to inhibit vlPAG MOR-expressing GABAergic interneurons12,19,22,39,43,47,65,114,150,183-
186,264-282, our data suggest that TLR4 signaling contributes to opioid tolerance by decreasing the 
ability of morphine to hyperpolarize vlPAG GABAergic interneurons, thereby maintaining tonic 
inhibition of vlPAG-RVM projections neurons, and preventing opioid analgesia.  
Summary 
The midbrain periaqueductal gray (PAG), and its descending projections to the rostral 
ventromedial medulla (RVM) and spinal cord, comprises an essential neural circuit for opioid-
mediated analgesia9,11,12,175,283. PAG-mediated analgesia depends largely upon the ability of 
opioids to inhibit vlPAG MOR-expressing GABAergic interneurons12,19,22,39,43,47,65,114,150,183-
186,264-282, thereby releasing PAG-RVM projection neurons from tonic inhibition34,36. A multitude 
of studies have demonstrated that the vlPAG is both necessary and sufficient for the initiation 
and maintenance of morphine tolerance24,49. Indeed, our lab reported that tolerance to systemic 
morphine is accompanied by the inability of acute systemic opioids to activate the PAG-RVM 
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circuit in male rats45. Studies outlined within this dissertation tested the overarching hypothesis 
that morphine-induced vlPAG glia activity contributes to morphine tolerance.  Opioids, 
including morphine, bind to the glial receptor TLR4 resulting in the robust release of 
proinflammatory cytokines (including tumor necrosis factor a; TNF)78,79. TLR4 and TNF 
signaling increase neuronal excitability in a number of model systems54,102,120,145, and are 
strongly implicated in opioid tolerance development54,78,102. This dissertation specifically 
identified the role of TLR4 and TNF in the development of morphine tolerance in a CNS region 
critical for opioid induced analgesia: the midbrain vlPAG. 
We hypothesized that vlPAG glia modulate the analgesic efficacy of morphine via 
signaling through the innate immune receptor TLR4 and downstream products of the TLR4 
signaling cascade, specifically via the cytokine TNF. In particular, we postulated that morphine 
binds to neuronal MOR as well as glial TLR4 in the PAG, and that concurrent activity at these 
receptors modulates the analgesic efficacy of morphine. Two opposing mechanisms were 
proposed: (1) opiate binding at MOR, resulting in hyperpolarization of GABAergic neurons and 
induction of opiate analgesia; and (2) opiate binding at glial TLR4 leading to increased vlPAG 
cytokine signaling and increased neuroexcitability. This increase in vlPAG neuroexcitability 
opposes the hyperpolarizing effects of opiates and limits the inability of morphine to disinhibit 
the PAG-RVM circuit (Figure 5.1). These hypotheses were tested in four specific aims.  
With these data, glia modulation of opioid tolerance has been reported at every major 
level of the descending analgesic circuit: PAG, RVM, and spinal cord dorsal horn. Our results 
are the first to identify (1) a role for PAG glia in the development of morphine tolerance;  (2) a 
neural locus through which TLR4 modulates morphine tolerance development;  (3) solTNF as 
the important TNF form mediating opioid tolerance and alterations in glutamate homeostasis; 
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and (4) release of PAG cytokines in the development of morphine tolerance. Additionally, these 
studies identify the anti-TNF biologic XPro®1595 as a potential tool to accompany opioid 
therapy in the clinic. XPro®1595 may be preferable over current FDA approved anti-TNF 
biologics (Etanercept, Inflliximab, Adalimumab) as these drugs block both forms of TNF and are 
associated with encephalic lesions, neuritis, multiple sclerosis, and other demyelinating 
diseases194. Here we have demonstrated that exclusive sequestration of solTNF prevents opioid 
induced neuroinflammation and the ensuing changes in glutamate homeostasis and development 
of morphine tolerance. Importantly, these data indicate that tmTNF signaling (TNFRI and 
TNFRII) does not contribute to opioid tolerance. As TNFRII is protective against glutamate 
excitotoxicity231, these data indicate that TNFRII signaling may be a critical countermeasure to 
opioid-induced neuroexcitability.  
Our results suggest that XPro®1595 may be an ideal drug candidate to pursue clinically. 
Interestingly, glia, TLR4, and TNF have all been implicated in the increased nociception that 
characterizes painful neuropathic diseases including neuropathic pain and rheumatoid arthritis71. 
The mechanisms underlying glia mediated hyperalgesia are strikingly similar to the mechanisms 
underlying opioid tolerance development71, indicating that anti-TNF biologics could complement 
opioid therapy in the clinic by suppressing nociceptive signals at the site of injury and in the 
spinal cord, as well as preserving morphine analgesic efficacy by preventing opioid-induced glia 
activation within the vlPAG, thereby attenuating the development of  morphine tolerance. 
There are several questions that are left unanswered with the conclusion of this 
dissertation. Here we identify the following as important next logical steps; (1) Characterize the 
effects of TACE inhibition on spinal cord, RVM, and vlPAG glia activity and the development 
of morphine tolerance; (2) Characterize the effects of soluble TNF sequestration on the ability of 
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chronic and acute morphine to inhibit GABA release in the vlPAG and to maintain tonic 
inhibition of PAG-RVM projection neurons (via electrophysiological experiments and 
microdialysis); (3) Characterize the necessity and sufficiency of TLR4, TNF, and TACE to 
inhibit PAG-RVM signaling (fluorogold (FG) into the RVM with IHC) and neuronal activation 
within the PAG (Fos IHC)253. We would hypothesize a significant decrease in FG positive and 
Fos + colocalization in vlPAG cells in tolerant animals, as previously described by Morgan, 
Loyd, and Murphy (2006). We would predict that intraplantar CFA treatment (Chapter 2), TLR4 
antagonism (Chapter 3), soluble TNF sequestration (Chapter 4), or TACE antagonism (Chapter 
5) would maintain morphine analgesia by allowing for release of PAG-RVM circuit upon MOR 
binding. These manipulations may also prevent tolerance and rescue opioid analgesia; (4) Induce 
tolerance in animals given pain (e.g., CFA) by prolonging chronic morphine exposure until 
tolerance develops, and then characterize the effects of vlPAG glia, TLR4, soluble TNF, and 
TACE in tolerance development in a several different pain states (e.g., CFA, CCI, migraine, burn 
pain, and formalin); (5) Characterize the effects of vlPAG glia, TLR4, soluble TNF, and TACE 
in tolerance development using multiple behavioral measures of nociception and analgesia 
including thermal tests (e.g., Hargreaves paw thermal stimulator to stimulate thermal 
nociceptors; Chapter 2 – 4), mechanical tests (von Frey filament test to stimulate mechanical 
nociceptors), and visceral tests (visceral distention to stimulate silent nociceptors in the gut). 
These results will help determine which chronic pain conditions should be treated with morphine 
and anti-inflammatory therapy in the clinic; (6) Females should be made tolerant to morphine by 
using an effective dose for the sex and administering morphine until they show behavioral 
tolerance to multiple pain tests (mentioned in future directions 5). When tolerant, this 
dissertation should be repeated in females. The role of glia and TACE should also be 
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characterized in a model of migraine, as females have higher incidence of migraine, and 
migraine has a robust inflammatory component; (7) Finally, XPro®1595 should be characterized 
in all of the 6 hypotheses/future directions stated above. This drug has been successfully used as 
a neuroprotector in a Hemiparkinsonian rat model211,284, and soluble TNF has been implicated in 
increased blood brain barrier permeability in neurodegenerative diseases. Indeed, lenti-DN-TNF 
attenuates the symptoms associated with inflammation (cytokines), neuronal excitability, cell 
death, and cognitive impairment in rodent models of Alzheimer’s disease Parkinson’s disease207-
211,285-290. It is necessary for cognitive health to maintain tmTNF signaling191,231,291-293. 
XPro®1595 (BBB DN-TNF peptide) has exciting clinical potential as it sequesters the 
proinflammatory soluble TNF, while maintaining innate immunity to infection (e.g., tmTNF). 
Answering the above 7 questions, as well as delving into the pain and endocannabinoid story in 
males and females, will elucidate the role of neuroinflammation and neuroexcitability in the 
development of morphine tolerance and could enhance chronic morphine treatment for a variety 
of clinical pain conditions safely. These hypotheses remain to be rigorously tested. 
  
122 
Chapter 5 Figures 
 
 
Figure 5.1 A schematic diagram illustrating major dissertation conclusions. 
Chronic morphine binds to vlPAG TLR4 and leads to solTNF signaling that increases 
proinflammatory gene expression (TLR4, IL-1β) and decreases astrocytic glutamate transporter 
mRNA (GLT-1 and GLAST) in the vlPAG. These changes effectively increase the availability of 
glutamate in the synapse, thereby decreasing the ability of morphine to hyperpolarize 
GABAergic interneurons. These changes associated with morphine tolerance prevent morphine 
from initiating signaling through the descending analgesic circuit. The next step is to inhibit 
TACE to test our hypothesis that TACE mediates TLR4 mediated soluble TNF signaling and 
glutamatergic alterations in the vlPAG to alter tolerance to mu opioid receptor agonists.  
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